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SUMMARY
Many papers have introduced adaptive clinical trial methods that allow modifications to the sample size
based on interim estimates of treatment effect. There has been extensive commentary on type I error control
and efficiency considerations, but little research on estimation after an adaptive hypothesis test. We evaluate
the reliability and precision of different inferential procedures in the presence of an adaptive design with pre-
specified rules for modifying the sampling plan. We extend group sequential orderings of the outcome space
based on the stage at stopping, likelihood ratio test statistic, and sample mean to the adaptive setting in order
to compute median-unbiased point estimates, exact confidence intervals, and P-values uniformly distributed
under the null hypothesis. The likelihood ratio ordering is found to average shorter confidence intervals and
produce higher probabilities of P-values below important thresholds than alternative approaches. The bias
adjusted mean demonstrates the lowest mean squared error among candidate point estimates. A conditional
error-based approach in the literature has the benefit of being the only method that accommodates unplanned
adaptations. We compare the performance of this and other methods in order to quantify the cost of failing
to plan ahead in settings where adaptations could realistically be pre-specified at the design stage. We find
the cost to be meaningful for all designs and treatment effects considered, and to be substantial for designs
frequently proposed in the literature.
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1 Introduction
Adaptive clinical trial design has been proposed as a promising new approach that may help improve the
efficiency of the drug discovery process. In particular, many papers have introduced methods that control the
false positive rate while allowing modifications to the sample size based on interim estimates of treatment
effect (e.g., Bauer & Kohne, 1994; Proschan & Hunsberger, 1995; Fisher, 1998; Cui, Hung, & Wang,
1999; Mu¨ller & Scha¨fer, 2001). Some researchers have suggested that the potential gains in flexibility and
efficiency achieved by these adaptive procedures may not be worth the added challenges in interpretability,
logistics, and ethics (Jennison & Turnbull, 2006a; Fleming, 2006; Levin, Emerson, & Emerson, 2012).
However, adaptive designs are being proposed and implemented in actual clinical research, so investigators
need the tools to interpret results after an adaptive hypothesis test has been carried out.
In its draft guidance on adaptive clinical trials (Food and Drug Administration, 2010), the Food and Drug
Administration (FDA) identifies as a principal issue “whether the adaptation process has led to positive study
results that are difficult to interpret irrespective of having control of Type I error.” Confirmatory phase III
clinical trials need to produce results that are interpretable, in that sufficiently reliable and precise inferential
statistics can be computed at the end of the study. This helps ensure that regulatory agencies approve
new treatment indications based on credible evidence of clinically meaningful benefit to risk profiles and
appropriately label new treatments, thus enabling clinicians to effectively practice evidence-based medicine.
In the presence of sequential hypothesis testing (group sequential or adaptive), it is inappropriate to
base inference on fixed sample estimates and P-values. The normalized Z statistic is no longer normally
distributed and the fixed sample P-value is no longer uniformly distributed under the null hypothesis. In
the setting of a group sequential design, orderings of the outcome space have been proposed based on
the analysis time (Armitage, 1957; Tsiatis, Rosner, & Mehta, 1984), the likelihood ratio statistic (Chang
& O’Brien, 1986; Chang, 1989), and the sample mean (Emerson & Fleming, 1990) at stopping. These
orderings allow the computation of median-unbiased point estimates, confidence sets with exact coverage,
and P-values uniformly distributed over [0,1] under the null. Several authors have proposed criteria by
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which different orderings of the outcome space should be judged and rigorously evaluated their behavior in
the group sequential setting (Tsiatis et al., 1984; Chang & O’Brien, 1986; Rosner & Tsiatis, 1988; Chang,
1989; Emerson & Fleming, 1990; Chang, Gould, & Snapinn, 1995; Gillen & Emerson, 2005; Jennison &
Turnbull, 2000).
While there is extensive research evaluating the precision of inference under different orderings of the
outcome space after a group sequential hypothesis test, little such research has been conducted in the adap-
tive setting. Brannath, Ko¨nig, and Bauer (2006) present a nice overview of a few of the proposed methods
for estimation, and offer some limited comparisons of properties of point and interval estimates. Lehmacher
and Wassmer (1999) and Mehta et al. (2007) extended the repeated confidence interval (CI) approach of
Jennison and Turnbull (2000) to adaptive hypothesis testing. A single repeated CI is only guaranteed to
provide conservative coverage. Brannath, Mehta, and Posch (2009) extended analysis time ordering-based
confidence intervals to the adaptive setting by inverting adaptive hypothesis tests based on preserving the
conditional type I error rate (Denne, 2001; Mu¨ller & Scha¨fer, 2001). However, since the conditional error
approach places different weights on subjects from different stages, violates the sufficiency principle, and
is an inefficient method of adaptive hypothesis testing (Tsiatis & Mehta, 2003; Jennison & Turnbull, 2003,
2006a), the corresponding ordering of the outcome space may be suboptimal. To our knowledge, no authors
have investigated the relative behavior of this and alternative orderings of the outcome space with respect to
the reliability and precision of inference in the adaptive setting.
Liu and Anderson (2008) introduced a general family of orderings of the outcome space for an adaptive
test analogous to the family of orderings discussed by Emerson and Fleming (1990) for a group sequential
test statistic. However, as noted by Chang, Gould, and Snapinn (1995), such an approach would for ex-
ample result in inference based on the likelihood ratio ordering when using Pocock stopping boundaries,
but inference based on a score statistic ordering when using O’Brien and Fleming boundaries. Because the
relative behavior of these different orderings has not been evaluated in the adaptive setting, and because Liu
and Anderson provide no comparisons of important properties such as mean squared error (MSE) of point
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estimates or expected CI length, it is unclear if this is a satisfactory approach.
In this manuscript, we investigate candidate inferential procedures for the setting of an adequate and
well-controlled confirmatory, phase III randomized clinical trial (RCT) with adaptive sample size modifi-
cation. In section 2, we motivate and introduce a class of pre-specified designs allowing unblinded interim
modifications to the sampling plan. In section 3, we generalize group sequential orderings of the outcome
space to the adaptive setting and outline methods for computing point estimates, confidence intervals, and
P-values. In section 4, we compare these orderings, as well as the inferential procedure proposed by Bran-
nath, Mehta, and Posch (2009), with respect to important criteria evaluating the reliability and precision of
inference. We conclude with a discussion of our findings.
2 Pre-specified Adaptive Designs with Interim Modifications to the Sam-
pling Plan
In this research, we focus on pre-specified adaptive designs that allow interim modification to only statistical
design parameters, i.e., to only the sampling plan. One reason to focus on pre-specified adaptations is
the lack of regulatory support, in the setting of adequate and well-controlled phase III trials, for methods
that allow unplanned modifications to the design (European Medicines Agency Committee for Medicinal
Products for Human Use, 2007; Food and Drug Administration, 2010). In addition, by developing a class of
pre-specified adaptive sampling plans, we provide a framework to evaluate the behavior both of inferential
procedures requiring pre-specification and of those methods that accommodate unplanned design changes.
Therefore, in RCT settings where adaptive sampling plans could realistically be pre-specified at the design
stage, comparisons of these two types of methods will directly quantify the cost of failing to plan ahead. In
settings where adaptive modifications were not pre-specified, our investigations allow the assessment of any
potential loss of precision from not being able to base inference on the minimal sufficient statistic.
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2.1 Setting
Consider the following simple setting of a balanced two-sample comparison, which is easily generalized
(e.g., to a binary or survival endpoint, Jennison & Turnbull, 2000). Potential observations XAi on treatment
A and XBi on treatment B, for i = 1,2, ..., are independently distributed, with means µA and µB, respectively,
and common known variance σ2. The parameter of interest is the difference in mean treatment effects,
θ = µA−µB. There will be up to J interim analyses conducted with sample sizes N1,N2,N3, ...,NJ accrued
on each arm (both J and the N js may be random variables). At the jth analysis, let S j = ∑
N j
i=1(XAi−XBi)
denote the partial sum of the first N j paired observations, and define θˆ j = 1N j S j = XA, j−XB, j as the estimate
of the treatment effect θ of interest based on the cumulative data available at that time. The normalized Z
statistic and upper one-sided fixed sample P-value are transformations of that statistic: Z j =
√
N j
θˆ j−θ0√
2σ2
and
Pj = 1−Φ(Z j). We represent any random variable (e.g. N j) with an upper-case letter and any realized value
of a random variable (e.g. N j = n j) or fixed quantity with a lower-case letter. We additionally use a * to
denote incremental data. We define N∗j as the sample size accrued between the ( j− 1)th and jth analyses,
with N0 = 0 and N∗j = N j−N j−1. Similarly, the partial sum statistic and estimate of treatment effect based
on the incremental data accrued between the ( j− 1)th and jth analyses are S∗j = ∑N ji=N j−1+1(XAi−XBi) and
θˆ∗j =
1
N∗j
S∗j , respectively.
Assume that the potential outcomes are immediately observed. Without loss of generality, assume that
positive values of θ indicate superiority of the new treatment. It is desired to test the null hypothesis H0 : θ=
θ0 = 0 against the one-sided alternative θ> 0 with type I error probability α= 0.025 and power β at θ= ∆.
The alternative hypothesis θ = ∆ represents an effect size that would be considered clinically meaningful
when weighed against such treatment characteristics as toxicity, side effects, and cost. First consider a
simple fixed sample design, which requires a fixed sample size on each treatment arm of n = 2σ
2 (z1−α+zβ)2
∆2 .
One may also consider a group sequential design (GSD), for which we use the following general
framework (Kittelson & Emerson, 1999). At the jth interim analysis, we compute some statistic Tj =
T (X1, ...,XN j) based on the first N j observations. Then, for specified stopping boundaries a j ≤ d j, we stop
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with a decision of non-superiority of the new treatment if Tj ≤ a j, stop with a decision of superiority of the
new treatment if Tj ≥ d j, or continue the study if a j < Tj < d j. We restrict attention to families of stopping
rules described by the extended Wang and Tsiatis unified family (1987), in which the P parameter reflects
the early conservatism of the stopping boundaries.
2.2 A Class of Pre-specified Adaptive Designs
We now introduce a class of completely pre-specified adaptive designs. Consider a sequential design that
may contain one “adaptation” analysis at which the estimate of treatment effect is used to determine the
future sampling plan, i.e., the schedule of analyses and choice of stopping boundaries. It is single-adaptation
designs that are typically proposed in the literature. The following notation will be used to describe a class
of such pre-specified adaptive designs:
• Continuation and stopping sets are defined on the scale of some test statistic Tj, for j = 1, . . . ,J.
• The adaptation occurs at analysis time j = h. Continuation sets at analyses prior to the adaptation
analysis ( j = 1, . . . ,h−1) are denoted C0j . Analyses up through the adaptation analysis ( j = 1, . . . ,h)
occur at fixed sample sizes denoted n0j .
• At the adaptation analysis ( j = h), there are r continuation sets, denoted Ckh, k = 1, . . . ,r, that are
mutually exclusive, Ckh ∩Ck
′
h = /0 for k 6= k′, and cover all possible outcomes that do not lead to early
stopping at analysis time j = h.
• Each continuation set Ckh at the adaptation analysis corresponds to a group sequential path k, with
a maximum of Jk interim analyses and continuation regions Ckh+1, . . . ,C
k
Jk corresponding to future
analyses at sample sizes nkh+1, . . . ,n
k
Jk (with C
k
Jk = /0 for k = 1, . . . ,r).
• The random sample path variable K can take values 0,1, . . . ,r, where K = 0 indicates that the trial
stopped at or before the adaptation analysis and K = k for k = 1, . . . ,r indicates that Th ∈ Ckh at the
adaptation analysis, so that group sequential path k was followed at future analyses.
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• The stopping sets and boundaries are denoted and defined as S 0j = S 0(0)j ∪S 0(1)j = (−∞,a0j)∪ (d0j ,∞),
j = 1, . . . ,h and S kj = S
k(0)
j ∪S k(1)j = (−∞,akj)∪ (dkj ,∞), k = 1, . . . ,r, j = h+1, . . . ,Jk.
• Define the test statistic (M,S,K) where M is the stage the trial is stopped, S ≡ SM is the cumulative
partial sum statistic at stopping, and K is the group sequential path followed.
Consider the following simple example. Suppose that we base inference on the estimate of treatment
effect θˆ j = XA, j−XB, j. At the first analysis, with sample size n1 accrued on each arm, we stop early for
superiority if θˆ1 ≥ d01 or non-superiority if θˆ1 ≤ a01. Now suppose that we add a single adaptation region
inside the continuation set (a01,d
0
1) at the first analysis. Conceptually, the idea is that we have observed results
sufficiently far from our expectations and from both stopping boundaries such that additional data (a larger
sample size) might be desired. Denote this adaptation region C21 = [A,D] where a
0
1 ≤ A ≤ D ≤ d01 . Denote
the other two continuation regions C11 = (a
0
1,A) and C
3
1 = (D,d
0
1). Under this sampling plan, if θˆ1 ∈ Ck1,
we continue the study, proceeding to fixed sample size nk2, at which we stop with a decision of superiority
if θˆ2 ≥ dk2, where θˆ2 ≡ θˆ(nk2) = 1nk2 ∑
nk2
i=1(XAi− XBi), for k = 1,2,3. Figure 1 illustrates the stopping and
continuation boundaries for one such sequential sampling plan, in which the design is symmetric so that
n12 = n
3
2 and d
1
2 = d
2
2 = d
3
2 = d2 (on the sample mean scale).
2.3 Sampling Density and Operating Characteristics
Appealing to the Central Limit Theorem, we have approximate distributions S∗1 ∼ N(n01 θ, 2n01σ2) and
S∗j |S j−1 ∼ N(nk∗j θ, 2nk∗j σ2) since N∗j = nk∗j is fixed conditional on S j−1 = s ∈ Ckj−1 (k = 0, j = 1, . . . ,h
and k = 1, . . . ,r, j = h+ 1, . . . ,Jk). Therefore, for pre-specified continuation and stopping sets, following
Armitage, McPherson, and Rowe (1969), the sampling density of the observed test statistic (M = j,S =
s,K = k) is
pM,S,K( j, s, k; θ) =

fM,S,K( j, s, k; θ) if s ∈ S kj
0 otherwise
(1)
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where the (sub)density is recursively defined as
fM,S,K(1, s, 0; θ) =
1√
2n01σ
φ
 s−n01 θ√
2n01σ

fM,S,K( j, s, k; θ) =
∫
Ckj−1
1√
2nk∗j σ
φ
s−u−nk∗j θ√
2nk∗j σ
 fM,S,K( j, u, k;θ) du
for k = 0, j = 2, . . . ,h (if h > 1) and k = 1, . . . ,r, j = h+1, . . . ,Jk. It is easy to show that the following holds:
pM,S,K( j, s, k; θ) = pM,S,K( j, s, k; 0)exp
(
sθ
2σ2
− θ
2
4σ2
nkj
)
. (2)
Given this relation, we can see that the maximum likelihood estimate (MLE) is the sample mean θˆ= s/nkj.
In addition, the two-dimensional test statistic composed of the cumulative partial sum S and sample size N
at stopping is minimally sufficient for the unknown mean treatment effect θ. We can easily compute the
sampling density of this sufficient statistic, or of the partial sum statistic or MLE.
Because we can write out and numerically evaluate the sampling density of the test statistic (M,T,K),
we can compute frequentist operating characteristics, such as type I error, power, and expected sample size
(ASN). Since the operating characteristics of such pre-specified adaptive sampling plans are just functions
of the operating characteristics of a set of group sequential designs, we can amend existing group sequential
software to carry out these computations. All of our computations were performed using the R package
RCTdesign built from the S-Plus module S+SeqTrial (S+SeqTrial, 2002).
3 Complete Inference after an Adaptive Hypothesis Test
Complete frequentist inference typically consists of four numbers: a point estimate of treatment effect,
a confidence interval providing a range of effect sizes consistent with the observed data, and a P-value
describing the strength of statistical evidence against the hypothesis of no effect.
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3.1 Exact Confidence Sets and Orderings of the Outcome Space
We construct confidence sets based on the duality of hypothesis testing and confidence interval estimation.
The confidence set consists of all hypothesized values for the parameter θ that would not be rejected by an
appropriately sized hypothesis test given the observed data. Formally, we define equal tailed (1− 2α)×
100% confidence sets for θ by inverting a family of hypothesis tests with two-sided type I error probability
2α. As in the group sequential setting, we define an acceptance region of “non-extreme” results for the test
statistic (M,T,K) for each possible value of θ: A(θ,α) = {( j, t,k) : 1−α > P[ (M,T,K)  ( j, t,k); θ ] > α}
where  indicates “greater.” We then use this acceptance region to define a (1−2α)×100% confidence set
as CSα(M,T,K) = {θ : (M,T,K) ∈ A(θ,α)}. In order to apply this in practice, however, we need to define
“more extreme” by imposing an ordering on the three-dimensional outcome (sample) space Ω= {( j, t,k) :
t ∈ S kj ; k = 0, j = 1, . . . ,h and k = 1, . . . ,r, j = h+1, . . . ,Jk}.
The outcome space actually consists of nkj observations on each treatment arm. However, most intu-
itively reasonable orderings will rank outcomes only on the basis of information contained in the statistic
(M,T,K), or the minimal sufficient statistic (N,T ). The Neyman-Pearson Lemma indicates that, for a sim-
ple alternative hypothesis H1 : θ= ∆, the most powerful level α test is based on the likelihood ratio statistic.
However, clinical trialists are generally interested in composite alternative hypotheses consisting of a range
of plausible, clinically meaningful treatment effects. Just as in the group sequential setting, the probability
density function for an adaptive design does not have monotone likelihood ratio (see Supplementary section
2.2), so the theory for optimal tests and confidence intervals (Lehmann, 1959) in the presence of a composite
alternative hypothesis does not apply.
Because there is no clear best choice of an ordering for the outcome space, it is useful to evaluate the
behavior of a variety of different orderings with respect to a range of important properties. In the group
sequential setting, the most widely studied and implemented orderings are based on the stage at stopping,
the sample mean, and the likelihood ratio test statistic. We extend these three group sequential orderings
to the setting of a pre-specified adaptive design. We also consider CIs derived by inverting conditional
9
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error-based adaptive hypothesis tests, as proposed by Brannath, Mehta, and Posch (BMP) (2009).
Assume that continuation and stopping sets have been defined on the scale of the sample mean statistic
T ≡ θˆ. Consider the following orderings:
• Sample mean ordering (SM). Outcomes are ordered according to the value of the maximum likelihood
estimate, which is the sample mean T : ( j′, t ′,k′) ( j, t,k) if t ′ > t.
• Signed likelihood ratio ordering (LR). Outcomes are ordered according to the value of the signed
likelihood ratio test statistic against a particular hypothesized parameter value θ′:
( j′, t ′,k′)θ′ ( j, t,k) if sign(t ′−θ′) pM,T,K( j
′, t ′,k′; θ= t ′)
pM,T,K( j′, t ′,k′; θ= θ′)
> sign(t−θ′) pM,T,K( j, t,k; θ= t)
pM,T,K( j, t,k; θ= θ′)
.
Utilizing relation 2, this ordering simplifies to: ( j′, t ′,k′) θ′ ( j, t,k) if
√
nk′j′(t
′−θ′) >
√
nkj(t−θ′).
There is a different likelihood ratio ordering for each hypothesized value of the parameter of interest.
• Stage-wise orderings. Outcomes are ordered according to the “stage” at which the study stops. In the
group sequential setting, the rank of the sample sizes is equivalent to the rank of the analysis times, so
there is only one “analysis time” or “stage-wise” ordering. In the adaptive setting, there are an infinite
number of ways to extend and impose a stage-wise ordering. We have considered three reasonable
extensions of the stage-wise ordering (see Supplementary section 2.2 for details). One stage-wise
ordering of interest ranks observations according to the analysis time at which the study stops, with
ties broken by the value of a re-weighted cumulative Z statistic Zw. We consider the Cui, Hung, and
Wang statistic (1999), which maintains the same weights for the incremental normalized statistics Z∗j
as under the original fixed sample or group sequential design.
We note that some investigators (e.g., Jennison & Turnbull, 2000) have stated a preference for the
stage-wise ordering in the group sequential setting primarily because corresponding estimates and
P-values depend only on the observed data and the stopping rules of analyses that have already been
carried out. This is desirable because the interim analyses of most clinical trials occur at unpredictable
10
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information sequences, as Data Monitoring Committee (DMC) meetings need to be scheduled in ad-
vance. Importantly, this advantage does not extend to the setting of a pre-specified adaptive design,
because all of the stage-wise orderings we have considered depend on the sampling plan under al-
ternative sample paths. In addition, we have found extensions of the stage-wise ordering to produce
inferior behavior to alternative orderings with respect to important measures of the reliability and pre-
cision of inference. Therefore, we primarily focus on the sample mean, likelihood ratio, and BMP
orderings in this paper, although results based on the Zw ordering are included in Figures 4 and 5 for
completeness. See Supplementary section 3.2 for additional results.
• Conditional Error Ordering (BMP). Defined by Brannath, Mehta, and Posch (2009), outcomes are
ordered according to the level of significance for which a conditional error-based one-sided adaptive
hypothesis test would be rejected, in which incremental P-values are computed based on the group
sequential stage-wise ordering. Like the likelihood ratio ordering, this procedure depends on the
hypothesized value of θ. In addition, if an adaptation has been performed, the BMP ordering depends
not only on the sufficient statistic (M,T,K), but additionally on the value th of the interim estimate of
treatment effect. It also depends on the specification of a reference group sequential design (GSD) for
conditional type I error computations. Formally, for testing against one-sided greater alternatives,
( j′, t ′,k′, t ′h)θ′,GSD ( j, t,k, th) if µ( j′, t ′,k′, t ′h; θ′,GSD) < µ( j, t,k, th; θ′,GSD)
where µ is defined as the smallest significance level under which H0 : θ= θ′ would have been rejected
given the observed data.
This ordering was described in a more intuitive way in a recently submitted manuscript by Gao,
Liu, and Mehta (2012). One computes µ as the stage-wise P-value of the “backward image,” in the
outcome space of the original GSD, of the observed test statistic (M,T,K) = ( j, t,k). The backward
image is simply defined as the outcome for which the stage-wise P-value for testing H0 : θ= θ′ under
11
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the original GSD, conditional on the interim estimate th, is equal to the analogous conditional stage-
wise P-value for the observed statistic under the adaptively chosen group sequential path. Thus, every
outcome under every potential adaptively chosen path (for which the conditional type I error would
have been preserved) is mapped to a single outcome in the sample space of the original GSD.
One important characteristic of this ordering is that it does not depend on the sampling plan we would
have followed had we observed different interim data. Brannath, Mehta, and Posch (2009) formally
derive and evaluate only one-sided confidence sets. However, as they briefly note in their discussion
and is formalized in the recently submitted paper by Gao, Liu, and Mehta (2012), this method can be
easily extended to two-sided confidence sets.
For any one of the above orderings O = o and an observed test statistic (M,T,K) = ( j, t,k), we can
define a (1−2α)×100% confidence set:
CSαo ( j, t,k) = {θ : 1−α > P[ (M,T,K)o ( j, t,k);θ ] > α}. (3)
Note that we need more information than is contained in the statistic (M,T,K) to apply the re-weighted Z
and BMP orderings. There is no guarantee that this confidence set will be a true interval. True intervals
are guaranteed only if the sequential test statistic (M,T,K) is stochastically ordered in θ under the ordering
O = o, i.e., if P[ (M,T,K) o ( j, t,k) ; θ ] is an increasing function of θ for each ( j, t,k) ∈ Ω. We prove
stochastic ordering in θ for the sample mean ordering (see Supplementary Appendix A) by generalizing
Emerson’s proof (1988) in the group sequential setting. Brannath, Mehta, and Posch (2009) demonstrate
that stochastic ordering does not hold for some adaptive designs under the conditional error-based ordering.
We have been unable to prove or find violations of stochastic ordering for the likelihood ratio ordering. In all
numerical investigations, we compute confidence intervals (θL,θU) through an iterative search for parameter
values θL and θU such that P[ (M,T,K) o ( j, t,k); θL ] = α and P[ (M,T,K) o ( j, t,k); θU ] = 1−α.
If stochastic ordering does not hold for the LR and BMP orderings, it is possible that CIs derived in this
12
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way have true coverage below or above the nominal level. For either ordering, one could also compute CIs
based on the infimum and supremum of the confidence set in (3) to ensure at least nominal coverage.
3.2 Point Estimates and P-values
We extend several methods for point estimation following a group sequential trial to the setting of a pre-
specified adaptive sampling plan. We define the following point estimates for the parameter θ of interest
given the observed test statistic (M,T,K) = ( j, t,k):
• Sample Mean. The sample mean θˆ≡ T is the maximum likelihood estimate: θˆ= XA−XB = t.
• Bias adjusted mean. The bias adjusted mean (BAM), proposed by Whitehead (1986) in the group
sequential setting, is easily extended to the setting of a pre-specified adaptive design. The BAM is
defined as the parameter value θˇ satisfying ET [T ; θˇ ] = t.
• Median-unbiased estimates. A median-unbiased estimate (MUE) is defined as the parameter value θ˜o
that, under a particular ordering of the outcome space O= o, satisfies P[ (M,T,K)o ( j, t,k); θ˜o ] = 12 .
A particular ordering of the outcome space can also be used to compute a P-value. For the null hy-
pothesis H0 : θ = θ0, we compute the upper one-sided P-value under an imposed ordering as P-valueo =
P[ (M,T,K)o ( j, t,k); θ0 ].
3.3 Optimality Criteria for the Reliability and Precision of Inference
For a given sequential statistical sampling plan satisfying the scientific constraints of a particular clinical
trial design setting, it is desirable to choose inferential procedures with the best achievable reliability and
precision. Many of the typical criteria for evaluating fixed sample estimates remain important in the se-
quential setting, but additional unique properties become of interest as well. Emerson (1988), Jennison and
Turnbull (2000), and others (Tsiatis et al., 1984; Chang & O’Brien, 1986; Rosner & Tsiatis, 1988; Chang,
1989; Emerson & Fleming, 1990; Chang et al., 1995; Gillen & Emerson, 2005) have enumerated desirable
13
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properties of confidence sets, point estimates, and P-values after a group sequential test, and these optimality
criteria readily generalize to the adaptive setting.
As mentioned previously, it is preferable that stochastic ordering holds, so that exact confidence sets are
guaranteed to be true intervals. Alternatively, we would hope that confidence sets have approximately exact
coverage for all practical designs. In addition, it is desirable for confidence intervals and P-values to agree
with the hypothesis test, a property which we will refer to as “consistency.” More specifically, consistency
means that P-values are less than the specified significance level and confidence intervals exclude the null
hypothesis if and only if the test statistic corresponds to a stopping set that was associated with a rejection
of the null hypothesis. We note that it is always possible to instead define rejection of the null hypothesis
based on any specific P-value.
As with a fixed sample or group sequential design, we also want confidence intervals to be as precise as
possible. The amount of statistical information available at the time of stopping is a random variable under
a sequential sampling plan, resulting in confidence intervals of varying lengths. Therefore, one reasonable
measure of precision is the expected CI length under different presumed values of θ, with shorter intervals
to be desired. Another relevant criterion is the probability of P-values falling below important thresholds,
such as 0.001 and 0.000625. The probability of obtaining very low P-values is an important consideration
in settings where a single confirmatory trial may be used as a “pivotal” study. The FDA occasionally
approves a new treatment indication based on a single pivotal adequate and well-controlled confirmatory
trial that has the statistical strength of evidence close or equal to that of two positive independent studies
(e.g. 0.0252 = 0.000625). Finally, we prefer point estimates with the best achievable accuracy and precision.
Standard measures include bias, variance, and mean squared error. Additionally, we may desire confidence
intervals to include those point estimates found to have the best behavior.
Because the sampling density does not have monotone likelihood ratio under any ordering of the out-
come space, we would not expect uniformly optimal tests or estimation procedures. Instead, as in the group
sequential setting, it is likely that the relative performance of different estimation procedures depends on
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both the adaptive sampling plan and the true treatment effect θ. In the next sections, we introduce and
implement a comparison framework to evaluate estimation methods through the simulation of clinical trials
across a wide range of different adaptive designs.
4 Comparison Framework
Consider the simple and generalizable RCT design setting described in section 2.1. Without loss of gen-
erality, let σ2 = 0.5, so that the alternative ∆ can be interpreted as the number of sampling unit standard
deviations detected with power β. Consider the class of pre-specified adaptive designs described in section
2.2. In order to cover a broad spectrum of adaptive designs, we allow many parameters to vary.
We vary the the degree of early conservatism by deriving adaptive designs from reference group sequen-
tial designs with either O’Brien and Fleming (OF) (1979) or Pocock (1977) stopping boundaries. We vary
the power at θ= ∆ from 0.80 to 0.975. We consider adaptive designs with sample paths for which the max-
imum number of analyses J ranges from two to eight. We vary the timing of the adaptation by considering
adaptation analyses occurring between 25% and 75% of the original maximal sample size, and as early as
the first and as late as the third interim analysis. We consider designs with a maximum allowable sample size
NJmax representing a 25%, 50%, 75%, or 100% increase in the maximal sample size of the original design.
Finally, we vary the rule for determining the final sample size. We derive adaptive designs with two
different classes of functions of the interim estimate of treatment effect used to adaptively determine the
maximal sample size (see, e.g., Figure 2). First, we consider the following quadratic function of the sample
mean T = t observed at the adaptation analysis: NJ(t) = NJmax −a(t− d
0
h−a0h
2 )
2, where a is chosen to satisfy
the desired power β. The use of such a symmetric function, with the maximal sample size increase at the
midpoint of continuation region of the original GSD, approximates the sample size rules that we (Levin et
al., 2012) and others (Posch, Bauer, & Brannath, 2003; Jennison & Turnbull, 2006b) have observed to be
nearly optimal in investigations of the efficiency of different adaptive hypothesis tests. Second, we consider
adaptation rules in which the final sample size NJ(t) is determined in order to maintain the conditional
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power (CP) at a pre-specified desired level, presuming the interim estimate of treatment effect is the truth
(θ= t). We set this level at the value of the unconditional power set for θ=∆ in the original group sequential
design. Although we do not recommend the use of conditional power-based sample size functions (Levin
et al., 2012), they are frequently proposed in the literature (e.g., Proschan & Hunsberger, 1995; Wassmer,
1998; Cui et al., 1999; Denne, 2001; Brannath, Posch, & Bauer, 2002; Brannath et al., 2006; Gao, Ware,
& Mehta, 2008; C. R. Mehta & Pocock, 2011). Thus, it is important to evaluate the behavior of inference
in the presence of such sampling plans. For both symmetric and conditional power-based sample size
functions, we allow no greater than a 25% decrease in the final sample size of the original GSD. We also
require that interim analyses occur after the accrual of at least 20% of the number of participants in the
previous stage. We imposed these restrictions to keep designs as realistic as possible: drastic decreases in an
originally planned sample size are typically not desirable or practical, and the scheduling of Data Monitoring
Committee meetings very close together is not logistically reasonable.
We consider adaptive hypothesis tests with r = 10 equally sized continuation regions and corresponding
potential sample paths because our research has demonstrated that including more than a few regions leads
to negligible efficiency gains (Levin et al., 2012). Increasing or decreasing r has negligible impact on the
relative behavior of inferential methods. The final sample size nkJ to which the trial will proceed if the interim
estimate of treatment effect falls in continuation region Ckh is determined by the sample size function NJ(t)
evaluated at the midpoint of the continuation region, for k = 1, . . . ,r.
The final design parameters that must be determined are the thresholds for statistical significance akJ ≡ dkJ
at the final analysis of sample paths k = 1, . . . ,r. As previously mentioned, it is desirable for confidence
intervals and P-values to agree with the hypothesis test. Consistency under an imposed ordering O = o can
be guaranteed by choosing critical boundaries akj and d
k
j such that d
k
j o akj for all k and j, i.e., all superiority
outcomes are “greater” under that ordering than all non-superiority outcomes (under the null). In many
other statistical settings, CIs and P-values are computed based on different orderings of the outcome space.
For example, proportional hazards inference frequently involves testing with the score (log-rank) statistic
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but interval estimation based on the Wald statistic. This is typically not a concern in settings where the
probability of disagreement is quite low. However, in the adaptive setting, there can be an unacceptable
degree of inconsistency (see, e.g., Supplementary Figure 3.2). The probabilities that CIs disagree with the
test are frequently near 5% and approach 15% for particular designs and treatment effects. It is thus very
important to use the same ordering of the outcome space to carry out tests as to compute P-values and CIs.
In our design comparison framework, we therefore choose the final boundaries dkJ in order to ensure
(near) consistency between the adaptive hypothesis test and inference under a particular ordering of the out-
come space. The BMP ordering depends not only on the observed statistic (M,T,K) = ( j, t,k), but also on
the interim estimate th. Therefore, a unique dkJ is required for each potential value of ( j, t,k, th) to guarantee
consistency. However, with r = 10 sample paths and corresponding choices of dkJ , we have not yet observed
the probability of disagreement between test and CI to surpass 1%. If this is still considered unaccept-
able, one could increase r to ensure negligible disagreement without materially affecting the precision of
inference. That being said, we note that increasing the number of paths makes it more difficult to maintain
confidentiality and preserve trial integrity (Levin et al., 2012).
We illustrate our comparison framework using a simple example for which results on the reliability
and precision of inference will be presented in the following sections. Consider a reference O’Brien and
Fleming GSD with two equally spaced analyses and 90% power at θ = ∆. The GSD has analyses at 51%
and 101% of the fixed sample size n needed to achieve the same power. We derive an adaptive sampling plan
from the GSD that allows up to a 100% increase in the maximal sample size. We divide the continuation
region of the GSD at the first analysis into ten equally sized regions Ck1,k = 1, . . . ,10, and determine each
corresponding final sample size nk2 by evaluating the quadratic function NJ(t) = 2.02n− 1.627(t− 1.96)2
at the region’s midpoint (a = 1.627 was chosen so that the adaptive test attains 90% power at θ = ∆). We
consider several different adaptive hypothesis tests, for which boundaries ak2 = d
k
2,k = 1, . . . ,10, are chosen
so that observed statistics on the boundaries at the final analysis are equally “extreme” under the sample
mean (SM), likelihood ratio (LR), or conditional error (BMP) orderings of the outcome space. All tests
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have the same sample size modification rule and thus the same average sample size at all θs. However, the
tests based on different orderings of the outcome space have contrasting functions for the final superiority
boundary and thus have slightly different power curves (Figure 3). Power differences in this example are
indicative of the general trends observed for the adaptive designs we have considered: likelihood ratio and
conditional error ordering-based hypothesis tests tend to lead to greater power at small treatment effects,
while sample mean ordering-based testing produces higher power at more extreme effects.
We use this extensive design comparison framework to evaluate the relative behavior of different esti-
mation procedures with respect to the characteristics described in section 3.3 that assess the reliability and
precision of inference. We perform numerical investigations based on 10,000 simulations under each of a
wide range of θs for each adaptive design. We present de-trended results in Figures in order to facilitate
conclusions about relative performance. Variance computations demonstrate that any visible separation be-
tween curves across contiguous regions of the parameter space provides statistically reliable evidence of a
true difference between the competing inferential methods (Supplementary section 3.5).
5 Results Comparing Different Inferential Procedures
We present results for representative two-stage adaptive designs, and describe trends when additional pa-
rameters of the adaptive design are varied. Detailed results across a wide range of adaptive sampling plans
are available in the supplementary materials (Supplementary chapter 3 and Appendix B).
5.1 Confidence Intervals
Table 1 displays the simulated coverage probabilities for a range of two-stage adaptive designs. Similar
results were observed when additional design parameters were varied. With 10,000 replications and 95%
nominal coverage, the standard error of the simulated coverage probability is 0.0022. These results suggest
that CI coverage is approximately exact under the SM, LR, and BMP orderings for the range of designs con-
sidered. As expected, naive 95% confidence intervals do not have exact coverage, with observed coverage
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probabilities typically 92-94%, and occasionally near 90%. It is a better choice to construct intervals using
methods that adjust for the sequential sampling plan.
Figure 4 presents average lengths of CIs based on the sample mean, likelihood ratio, conditional error,
and re-weighted Z orderings for two-stage adaptive designs derived from an O’Brien and Fleming design,
with varying functions for and restrictions on the maximal increase in the final sample size. The LR ordering
tends to produce approximately 1% to 10% shorter CIs than the SM and conditional error (BMP) orderings,
depending on the adaptive sampling plan and presumed treatment effect. These are large differences, as
interval length is inversely proportional to the square root of the sample size. It requires, for example, more
than a 20% increase in the sample size to achieve such a 10% reduction in CI length. The margin of superior-
ity for the LR ordering increases with the potential sample size inflation and is slightly greater for CP-based
than symmetric sample size modification rules. For this design, the sample mean and BMP orderings yield
similar expected CI lengths. When the adaptive tests are derived from Pocock group sequential designs, the
LR ordering remains best and the SM ordering produces approximately 1−3% shorter expected CI lengths
than the BMP ordering (Supplementary Figure 3.9). The stage-wise re-weighted Z ordering demonstrates
very poor relative behavior with respect to average CI length.
We have observed confidence intervals based on the sample mean, likelihood ratio, and conditional
error orderings to always contain the bias adjusted mean. This is desirable because results in section 5.2 will
demonstrate that the BAM tends to be both more accurate and precise than competing point estimates.
5.2 Point Estimates
Supplementary Table 5.2 displays the simulated probabilities that the true treatment effect θ exceeds each
MUE across a range of two-stage adaptive designs, demonstrating that the estimates are median-unbiased
within simulation error. Figure 5 compares the MSE of candidate point estimates for two-stage adaptive
designs derived from an O’Brien and Fleming group sequential design, with varying functions for and
restrictions on the maximal increase in the final sample size. The BAM tends to have mean squared error
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ranging from approximately 1 to 20% lower than competing median-unbiased estimates, depending on the
sampling plan, treatment effect, and MUE being compared. The margin of superiority increases with the
potential sample size inflation and tends to be slightly larger for CP-based than symmetric sample size
modification rules. MUEs based on the LR and SM orderings have up to approximately 15% lower MSE
than the MUE under the conditional error ordering. The LR ordering-based MUE is slightly superior (∼
1−3%) to the SM ordering-based MUE in some settings, but similar in others. The observed differences in
behavior between competing estimates tend to be greater for adaptive sampling plans derived from OF than
Pocock GSDs (Supplementary Figure 3.16).
The superior behavior of the BAM with respect to MSE tends to be due to lower bias at small and large
treatment effects and decreased variance at intermediate treatment effects (Supplementary Figures 3.12 -
3.14). It is also important to note that the MLE behaves poorly relative to the competing median-unbiased
and bias adjusted point estimates. The MLE has substantially higher bias than many other estimates at all
but intermediate treatment effects, and considerably higher mean squared error (up to ∼ 40% higher) across
nearly all designs and treatments effects considered (Figure 5 and Supplementary Figure 3.6).
5.3 P-values
The likelihood ratio ordering produces low P-values with substantially higher probabilities, up to 20%
greater on the absolute scale, than the sample mean and conditional error orderings (Figure 6). This su-
periority margin increases with the potential sample size inflation, and tends to be larger for CP-based than
symmetric sample size modification rules, and for adaptive sampling plans derived from OF as compared
to Pocock reference designs (Supplementary Figure 3.18). The SM ordering demonstrates superiority to
the BMP ordering in some settings, yielding up to approximately 10% higher probabilities, on the absolute
scale, of observing P-values below important thresholds. The stage-wise re-weighted Z ordering, based on
the Cui, Hung, and Wang statistic (1999), is equivalent to the BMP conditional error ordering under the
null hypothesis and therefore leads to the same probabilities of observing low P-values. The poor behavior
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of a stage-wise ordering with respect to this criterion is not surprising because similar findings have been
presented in the group sequential setting (Chang et al., 1995; Gillen & Emerson, 2007).
5.4 Varying Additional Design Parameters
Detailed results were presented in sections 5.1 through 5.3 on the relative behavior of inferential procedures
for simple two-stage adaptive sampling plans derived from a symmetric O’Brien and Fleming group sequen-
tial design. We discussed how the relative performance depends on the conservatism of the early stopping
boundaries (OF versus Pocock), the type of sample size modification rule (symmetric versus conditional
power-based), and the degree of potential sample size inflation (50% versus 100% increase). We have also
investigated the impact on inference of modifying the timing of the adaptation, the symmetry of the refer-
ence group sequential design, the power of the design at the alternative θ = ∆, and the number of interim
analyses (Supplementary Figures 3.19 - 3.24 and B.1 - B.15).
In the presence of either an early or late adaptation, the trends observed previously generally persist, but
quantitative differences between competing methods decrease. Of note, when the adaptation occurs early
in the trial, the relative behavior of inference based on the conditional error ordering improves. The MUE
remains substantially inferior to other point estimates with respect to MSE, but CIs tend to be shorter than
those based on the SM ordering, and nearly match the expected length of those under the LR ordering.
When considering asymmetric reference designs, qualitative trends generally persist, but the quantitative
differences between the different orderings with respect to the MSE of point estimates and expected length
of CIs tend to be smaller. In particular, the SM and BMP orderings now produce point and interval estimates
with very similar properties. Varying the power at θ= ∆ produces very similar results to those described in
sections 5.1 through 5.3. In addition, findings do not change when considering designs with sampling plan
modification at either the first or third interim analysis, or adaptations to sample paths containing between
two and eight interim analyses.
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6 Conclusions and the Cost of Planning not to Plan
In this research, we evaluated the reliability and precision of competing inferential methods across a wide
range of different adaptive designs through simulation experiments. The maximum likelihood estimate
and naive fixed sample confidence interval were observed to behave quite poorly. In addition, stage-wise
orderings of the outcome space based on the analysis time or statistical information at stopping produced
estimates and P-values with generally inferior behavior to comparators under alternative orderings.
The bias adjusted mean demonstrated the best behavior among candidate point estimates, with lower
bias at extreme effect sizes and lower mean squared error (up to ∼ 20% lower) across nearly all designs
and treatment effects considered. The likelihood ratio ordering tended to produce median-unbiased esti-
mates with lower MSE, confidence intervals with shorter expected length, and higher probabilities of low
P-values than the sample mean and conditional error orderings. In particular, LR ordering-based P-values
demonstrated substantially (up to ∼ 20% absolute) higher probabilities of reaching “pivotal” levels than
those based on alternative orderings. The superiority margin for inference based on the LR ordering tended
to be larger for greater sample size increases, and for conditional power-based than symmetric modification
rules. Sample mean ordering-based inference behaved similar to or slightly better than inference under the
conditional error ordering in most settings.
Our results also directly quantify what we describe as the “cost of planning not to plan.” In many
settings, if sample size modifications are of interest, the adaptive sampling plan and method of inference
could easily be and may need to be pre-specified. If the goal of an adaptation is to maintain conditional
power at some desired level, there is little reason why the sampling plan could not be established at the
design stage. In addition, the use of an unplanned adaptation to increase the sample size (and budget) of
a clinical trial may not be feasible for government or foundation-funded studies, and is discouraged by the
FDA (Food and Drug Administration, 2010).
If adaptations are not pre-specified, the conditional error (BMP) ordering is the only method presented
here that allows the computation of median-unbiased estimates, CIs with approximately exact coverage, and
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P-values uniformly distributed on [0,1]. If adaptations are instead pre-specified, any of the candidate order-
ings of the outcome space could be prospectively planned and used for inference. Therefore, by comparing
the behavior of inference based on the BMP and alternative orderings, we have quantified the cost of failing
to pre-specify the adaptation rule. Our results suggest that there is always a meaningful cost of planning
not to plan, and at times the cost can be substantial. Conditional error ordering-based confidence intervals
demonstrate expected lengths of typically only about 5% greater than those under the LR ordering (but note
that a 5% difference in expected length corresponds to a 10% difference in sample size). In addition, the
BMP MUE has substantially higher MSE (up to ∼ 25% higher) than the competing bias adjusted mean, and
the BMP P-value attains substantially lower probabilities (up to∼ 20% lower) than the LR P-value of falling
below important thresholds. Importantly, these losses are greatest when sample size modification rules are
based on conditional power and allow large inflation, i.e., for the kinds of sampling plans most typically
proposed in the literature. If an unplanned sample size modification is conducted during a clinical trial, the
BMP approach seems like a reasonable (and necessary) choice. However, if an adaptation could instead be
pre-specified at the design stage, inference involving the BAM and either the SM or LR ordering-based CIs
and P-values will tend to result in superior reliability and precision.
Our comparisons do not encompass the full space of potential adaptive designs, so it remains critical to
rigorously investigate candidate sampling plans and inferential procedures in any unique RCT setting where
an adaptive design is under consideration. Nevertheless, we have observed clear patterns that motivate some
general conclusions for the class of adaptive designs described in section 2.2. The bias adjusted mean is
the recommended point estimate due to its superior accuracy and precision than the MLE and competing
MUEs. The likelihood ratio ordering is supported by a tendency for shorter expected confidence interval
lengths and higher probabilities of potential pivotal P-values.
The choice of an ordering of the outcome space must also take into account power differences induced
by selecting boundaries to ensure consistency between hypothesis testing and inference. As discussed in
section 4, hypothesis testing based on the LR ordering tends to result in slightly greater power than the
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BMP ordering, and comparable power to the SM ordering (greater at intermediate treatment effects, lesser at
larger effects). However, adaptive hypothesis testing based on the LR and BMP orderings typically results in
a wide range of potential thresholds for statistical significance (see, e.g., Figure 3). This range of thresholds
may include values that fall below the minimal clinically important difference (MCID). As a result, we have
found that sample mean-based inference tends to demonstrate superior behavior to alternative orderings
when considering not statistical power, but instead the probability of obtaining an estimate at the end of the
trial that is both statistically and clinically significant. This consideration alone may warrant the choice of
SM-based rather than LR-based inference.
It is important to note that our research has focused on adaptive modifications only to the sampling plan.
Interim modifications to scientific aspects of the design, such as the treatment strategy or study population,
present additional challenges to the interpretability of results. The use of such adaptations, e.g. to seek
“adaptive enrichment,” may require inference on multiple treatment indications at the end of the study. In
addition, we have not addressed a number of important topics that require special consideration in the adap-
tive setting. Adaptive designs require increased effort in protocol development and lead to added challenges
in maintaining confidentiality. Additional considerations include the impact of time-varying treatment ef-
fects, the randomization ratio, and variance estimation, as well as challenges specific to longitudinal studies,
such as non-monotonic information growth and overrunning (see, e.g., Emerson, Rudser, & Emerson, 2011).
While our findings are therefore not able to demonstrate a single uniformly best inferential procedure for
any potential RCT, they do indicate general trends in performance that can be expected in typical settings.
At a minimum, we hope that our results motivate clinical trial investigators to carefully consider all of the
implications of using certain adaptive designs and inferential methods.
Supplementary Materials
Additional results and discussion are available in “Supplementary Materials for An Evaluation of Inferential
Procedures for Adaptive Clinical Trial Designs with Pre-specified Rules for Modifying the Sample Size.”
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Tables and Figures
Table 1: Simulated Coverage of 95% Confidence Intervals at Selected Power Points for Two-stage Adaptive
Sampling Plans Derived from O’Brien and Fleming (OF) and Pocock Group Sequential Designs, with Dif-
ferent Sample Size Modification Rules. The standard error of the simulated coverage probability is 0.0022.
OF Reference GSD Pocock Reference GSD
Power Naive SM LR BMP Naive SM LR BMP
Symmetric NJ function, up to 50% Increase
0.025 0.9442 0.9455 0.9449 0.9462 0.9425 0.9484 0.9485 0.9481
0.500 0.9314 0.9507 0.9488 0.9507 0.9458 0.9507 0.9504 0.9507
0.900 0.9402 0.9493 0.9478 0.9476 0.9350 0.9465 0.9467 0.9466
Symmetric NJ function, up to 100% Increase
0.025 0.9495 0.9487 0.9496 0.9493 0.9457 0.9484 0.9501 0.9496
0.500 0.9258 0.9467 0.9473 0.9466 0.9405 0.9465 0.9455 0.9466
0.900 0.9415 0.9505 0.9506 0.9511 0.9372 0.9498 0.9482 0.9501
CP-based NJ function, up to 50% Increase
0.025 0.9403 0.9455 0.9460 0.9461 0.9490 0.9530 0.9531 0.9530
0.500 0.9265 0.9512 0.9486 0.9507 0.9367 0.9466 0.9454 0.9468
0.900 0.9360 0.9480 0.9486 0.9469 0.9392 0.9513 0.9494 0.9513
CP-based NJ function, up to 100% Increase
0.025 0.9428 0.9494 0.9497 0.9494 0.9441 0.9502 0.9508 0.9505
0.500 0.9181 0.9462 0.9469 0.9466 0.9355 0.9461 0.9476 0.9462
0.900 0.9291 0.9501 0.9501 0.9501 0.9365 0.9494 0.9489 0.9496
SM = sample mean, LR = likelihood ratio, BMP = Brannath, Mehta, and Posch (conditional error)
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Figure 1: An illustration of possible continuation and stopping boundaries on the sample mean scale for a
pre-specified adaptive design.
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(b) Symmetric NJ function, up to 100% Increase
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(c) CP-based NJ function, up to 50% Increase
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(d) CP-based NJ function, up to 100% Increase
Figure 4: Expected length of different confidence intervals, as a proportion of the expected length of the
confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive tests derived
from an O’Brien and Fleming group sequential design. The sample size function is either symmetric about
the midpoint of the continuation region at the adaptation analysis or based on maintaining conditional power
(CP) at 90%, and is subject to the restriction of either a 50% or 100% maximal increase relative to the final
sample size of the reference group sequential design.
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(a) Symmetric NJ function, up to 50% Increase
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(b) Symmetric NJ function, up to 100% Increase
0.0 0.2 0.4 0.6 0.8 1.0
1.
0
1.
1
1.
2
1.
3
1.
4
Power
Pr
op
or
tio
n 
of
 B
AM
 M
ea
n 
Sq
ua
re
d E
rro
r BAMSM MUE
LR MUE
BMP MUE
Zw MUE
MLE
(c) CP-based NJ function, up to 50% Increase
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(d) CP-based NJ function, up to 100% Increase
Figure 5: Mean squared error of different point estimates, as a proportion of the mean squared error of the
bias adjusted mean, for pre-specified two-stage adaptive tests derived from an O’Brien and Fleming group
sequential design. The sample size function is either symmetric about the midpoint of the continuation
region at the adaptation analysis or based on maintaining conditional power (CP) at 90%, and is subject to
the restriction of either a 50% or 100% maximal increase relative to the final sample size of the reference
group sequential design.
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0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
Treatment Effect θ
Pr
ob
ab
ilit
y o
f L
ow
 P
−v
alu
e
0 0.25∆ 0.5∆ 0.75∆ ∆
SM
LR
BMP
< 0.001
< 0.000625
(d) CP-based NJ function, up to 100% Increase
Figure 6: Probabilities of obtaining P-values below important thresholds, for pre-specified two-stage adap-
tive tests derived from an O’Brien and Fleming group sequential design. The sample size function is either
symmetric about the midpoint of the continuation region at the adaptation analysis or based on maintaining
conditional power at 90%, and is subject to the restriction of either a 50% or 100% maximal increase relative
to the final sample size of the reference group sequential design.
Hosted by The Berkeley Electronic Press
Supplementary Materials for
An Evaluation of Inferential Procedures for Adaptive Clinical Trial
Designs with Pre-specified Rules for Modifying the Sample Size
by Gregory P. Levin, Sarah C. Emerson, and Scott S. Emerson
http://biostats.bepress.com/uwbiostat/paper388
Abstract
This report supplements the paper “An Evaluation of Inferential Procedures for Adaptive Clinical Trial De-
signs with Pre-specified Rules for Modifying the Sample Size” (2013) by presenting more comprehensive
simulation results and discussion. Many papers have introduced adaptive clinical trial methods that allow
modifications to the sample size based on interim estimates of treatment effect. There has been extensive
commentary on type I error control and efficiency considerations, but little research on estimation after an
adaptive hypothesis test. Confirmatory clinical trials need to produce results that are interpretable to ensure
that regulatory agencies approve new treatment indications based on credible evidence of clinically mean-
ingful benefit to risk and appropriately label new treatments, and to enable clinicians to effectively practice
evidence-based medicine. We evaluate the reliability and precision of different inferential procedures in the
presence of an adaptive design with pre-specified rules for modifying the sampling plan. We extend group
sequential orderings of the outcome space based on the stage at stopping, likelihood ratio test statistic, and
sample mean to the adaptive setting in order to compute median-unbiased point estimates, exact confidence
intervals, and P-values uniformly distributed under the null hypothesis. The likelihood ratio ordering is
found to average shorter confidence intervals and produce higher probabilities of P-values below important
thresholds than alternative approaches. The bias adjusted mean demonstrates the lowest mean squared error
among candidate point estimates. A conditional error-based approach in the literature has the benefit of
being the only method that accommodates unplanned adaptations. We compare the performance of this and
other methods in order to quantify the cost of failing to plan ahead in settings where adaptations could real-
istically be pre-specified at the design stage. We find the cost to be meaningful for all designs and treatment
effects considered, and to be substantial for designs frequently proposed in the literature.
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1Chapter 1
Pre-specified Adaptive Designs with Interim
Modifications to the Sampling Plan
1.1 Introduction
Adaptive designs can be classified into four groups by distinguishing between adaptive designs that are pre-
specified and those that allow unplanned changes, and between adaptive designs that allow modifications to
scientific aspects and those that allow modifications to only statistical aspects of the study. In this research,
we focus on pre-specified designs that allow interim modification to only statistical design parameters, i.e.,
to only the sampling plan. We have primarily restricted our attention to this class of designs for several
reasons.
We focus on statistical design modifications because we believe that adaptive sampling plans with in-
terim modifications to scientific design parameters largely compromise the ability of investigators to carry
out reliable and precise inference on a particular treatment indication at the end of the clinical trial. When
interim adaptations are made to scientific aspects of the design, the incremental null hypotheses and esti-
mands change during the trial and inference is required on multiple treatment indications. We do not believe
that there has been nearly enough rigorous research for the behavior of inference after any class of adaptive
design to be well-understood. It therefore makes sense to start with the simplest class of designs, in which
modifications are only made to the sampling plan.
One reason to focus on pre-specified adaptations is the lack of regulatory support, in the setting of
adequate and well-controlled phase III effectiveness trials, for methods that allow unplanned modifications
to the design (European Medicines Agency Committee for Medicinal Products for Human Use, 2007; Food
and Drug Administration, 2010). In addition, by developing a class of pre-specified adaptive sampling plans,
we provide a framework to evaluate the behavior both of inferential procedures requiring pre-specification
and of those methods that accommodate unplanned design modifications. Therefore, in RCT settings where
adaptive sampling plans could realistically be pre-specified at the design stage, comparisons of these two
http://biostats.bepress.com/uwbiostat/paper388
2types of methods will directly quantify the cost of failing to plan ahead.
1.2 Setting and Notation
Consider the following simple setting of a balanced two-sample comparison, which is easily generalized
(e.g., to a binary or survival endpoint, Jennison & Turnbull, 2000). Potential observations XAi on treatment
A and XBi on treatment B, for i = 1,2, ..., are independently distributed, with means µA and µB, respectively,
and common known variance σ2. The parameter of interest is the difference in mean treatment effects,
θ = µA−µB. There will be up to J interim analyses conducted with sample sizes N1,N2,N3, ...,NJ accrued
on each arm (both J and the N js may be random variables). At the jth analysis, let S j = ∑
N j
i=1(XAi−XBi)
denote the partial sum of the first N j paired observations, and define
θˆ j =
1
N j
S j = XA, j−XB, j (1.1)
as the estimate of the treatment effect θ of interest based on the cumulative data available at that time.
The normalized Z statistic and upper one-sided fixed sample P-value are transformations of that statistic:
Z j =
√
N j
θˆ j−θ0√
2σ2
and Pj = 1−Φ(Z j). We represent any random variable (e.g. N j) with an upper-case
letter and any realized value of a random variable (e.g. N j = n j) or fixed quantity with a lower-case letter.
We additionally use a * to denote incremental data. We define N∗j as the sample size accrued between
the ( j− 1)th and jth analyses, with N0 = 0 and N∗j = N j −N j−1. Similarly, the partial sum statistic and
estimate of treatment effect based on the incremental data accrued between the ( j− 1)th and jth analyses
are S∗j = ∑
N j
i=N j−1+1(XAi−XBi) and θˆ∗j = 1N∗j S
∗
j , respectively.
Assume that the potential outcomes are immediately observed. Without loss of generality, assume
that positive values of θ indicate superiority of the new treatment. It is desired to test the null hypothe-
sis H0 : θ= θ0 = 0 against the one-sided alternative θ> 0 with type I error probability α= 0.025 and power
β at θ= ∆. We assume that the alternative hypothesis θ= ∆ is based on the therapeutic index, and thus rep-
resents an effect size that would be considered clinically meaningful when weighed against such treatment
characteristics as toxicity, side effects, and cost. First consider a simple fixed sample design, which requires
a fixed sample size on each treatment arm of
n =
2σ2 (z1−α+ zβ)2
∆2
. (1.2)
One may also consider a group sequential design. We use the following general framework (Kittelson
& Emerson, 1999) for group sequential designs. At the jth interim analysis, we compute some statistic
Tj = T (X1, ...,XN j) based on the first N j observations. Then, for specified stopping boundaries a j ≤ d j, we
will stop with a decision of non-superiority of the new treatment if Tj ≤ a j, stop with a decision of superiority
of the new treatment if Tj ≥ d j, or continue the study if a j < Tj < d j. We restrict attention to families of
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3stopping rules described by the extended Wang and Tsiatis unified family (1987), in which the P parameter
reflects the early conservatism of the stopping boundaries. We could, for example, base inference on the
sufficient bivariate test statistic (M,S) where M is the stage the trial stops and S ≡ SM is the cumulative
partial sum statistic at the time of stopping.
1.3 A Class of Pre-specified Adaptive Designs
We now introduce a class of completely pre-specified adaptive designs. Consider a sequential design that
may contain one “adaptation” analysis at which the estimate of treatment effect is used to determine the
future sampling plan, i.e., the schedule of analyses and choice of stopping boundaries. We restrict attention
to designs with only one such adaptation analysis in order to first develop a better understanding of the
most straightforward adaptive sampling plans. In addition, it is single-adaptation designs that are typically
proposed in the literature. The following notation will be used to describe a class of such pre-specified
adaptive designs:
• Continuation and stopping sets are defined on the scale of some test statistic Tj, for j = 1, . . . ,J.
• The adaptation occurs at analysis time j = h. Continuation sets at analyses prior to the adaptation
analysis ( j = 1, . . . ,h−1) are denoted C0j . Analyses up through the adaptation analysis ( j = 1, . . . ,h)
occur at fixed sample sizes denoted n0j .
• At the adaptation analysis ( j = h), there are r continuation sets, denoted Ckh, k = 1, . . . ,r, that are
mutually exclusive: Ckh ∩Ck
′
h = /0 for k 6= k′.
• Each continuation set Ckh at the adaptation analysis corresponds to a group sequential path k, with a
maximum of Jk interim analyses (including the first h analyses) and continuation regions Ckh+1, . . . ,C
k
Jk
corresponding to future analyses at sample sizes nkh+1, . . . ,n
k
Jk . The constraint C
k
Jk = /0 for k = 1, . . . ,r
ensures that the study terminates by the maximum possible analysis time J (which may be a random
variable).
• The random sample path variable K can take values 0,1, . . . ,r, where K = 0 indicates that the trial
stopped at or before the adaptation analysis and K = k for k = 1, . . . ,r indicates that Th ∈ Ckh at the
adaptation analysis, so that group sequential path k was followed at future analyses (and the trial
stopped between analysis times h+1 and Jk).
• The stopping sets and boundaries are denoted and defined as S 0j = S 0(0)j ∪S 0(1)j = (−∞,a0j)∪ (d0j ,∞),
j= 1, . . . ,h and S kj = S
k(0)
j ∪S k(1)j = (−∞,akj)∪(dkj ,∞), k= 1, . . . ,r, j= h+1, . . . ,Jk. The superscripts
(0) and (1) indicate stopping sets for non-superiority and superiority, respectively. Note that the
stopping set at the adaptation analysis is S 0h = (C1h ∪· · ·∪Crh)c.
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4• Define the three-dimensional test statistic (M,S,K) where M is the stage when the trial is stopped,
S ≡ SM is the cumulative partial sum statistic at the time of stopping, and K is the group sequential
path that was followed.
Consider the following simple example. Suppose that we base inference on the estimate of treatment
effect equal to the difference in sample means: θˆ j = XA, j−XB, j. At the first analysis, with sample size n1
accrued on each arm, we stop early for superiority if θˆ1 ≥ d01 or non-superiority if θˆ1 ≤ a01. Now suppose
that we add a single adaptation region inside the continuation set (a01,d
0
1) at the first analysis. Conceptually,
the idea is that we have observed results sufficiently far from our expectations and from both stopping
boundaries such that additional data (a larger sample size) might be desired. We denote this adaptation
region C21 = [A,D] where a
0
1 ≤ A ≤ D ≤ d01 . Denote the other two continuation regions C11 = (a01,A) and
C31 = (D,d
0
1). The sampling plan proceeds as follows:
• if θˆ1 ≤ a01, stop with a decision of non-superiority;
• if θˆ1 ≥ d01 , stop with a decision of superiority;
• if θˆ1 ∈C11 , continue the study, proceeding to pre-specified, fixed sample size n12, at which stop with a
decision of superiority if θˆ2 ≥ d12 , where θˆ2 ≡ θˆ(n12) = 1n12 ∑
n12
i=1(XAi−XBi);
• if θˆ1 ∈C21 , continue the study, proceeding to pre-specified, fixed sample size n22, at which stop with a
decision of superiority if θˆ2 ≥ d22 , where θˆ2 ≡ θˆ(n22) = 1n22 ∑
n22
i=1(XAi−XBi);
• if θˆ1 ∈C31 , continue the study, proceeding to pre-specified, fixed sample size n32, at which stop with a
decision of superiority if θˆ2 ≥ d32 , where θˆ2 ≡ θˆ(n32) = 1n32 ∑
n32
i=1(XAi−XBi).
Figure 1.1 illustrates the stopping and continuation boundaries for one such sequential sampling plan,
in which the design is symmetric so that n12 = n
3
2 and d
1
2 = d
2
2 = d
3
2 = d2 (on the sample mean scale).
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Figure 1.1: An illustration of possible continuation and stopping boundaries on the sample mean scale for a
pre-specified adaptive design
1.4 Sampling Density
Appealing to the Central Limit Theorem, we have approximate distributions S∗1 ∼ N(n01 θ, 2n01σ2) and
S∗j |S j−1 ∼ N(nk∗j θ, 2nk∗j σ2) since N∗j = nk∗j is fixed conditional on S j−1 = s ∈ Ckj−1 (k = 0, j = 1, . . . ,h
and k = 1, . . . ,r, j = h+ 1, . . . ,Jk). Therefore, for pre-specified continuation and stopping sets, following
Armitage, McPherson, and Rowe (1969), the sampling density of the observed test statistic (M = j,S =
s,K = k) is
pM,S,K( j, s, k; θ) =
{
fM,S,K( j, s, k; θ) if s ∈ S kj
0 otherwise
(1.3)
where the (sub)density is recursively defined as
fM,S,K(1, s, 0; θ) =
1√
2n01σ
φ
 s−n01 θ√
2n01σ

fM,S,K( j, s, k; θ) =
∫
Ckj−1
1√
2nk∗j σ
φ
s−u−nk∗j θ√
2nk∗j σ
 fM,S,K( j, u, k;θ) du
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6for k = 0, j = 2, . . . ,h (if h > 1) and k = 1, . . . ,r, j = h+1, . . . ,Jk. Because
φ
s−u−nk∗j θ√
2nk∗j σ
= φ
 s−u√
2nk∗j σ
 exp( (s−u)θ
2σ2
− θ
2
4σ2
nk∗j
)
it is easy to show that the following holds:
pM,S,K( j, s, k; θ) = pM,S,K( j, s, k; 0)exp
(
sθ
2σ2
− θ
2
4σ2
nkj
)
. (1.4)
Given this relation, we can see that the maximum likelihood estimate is the sample mean θˆ= s/nkj. In addi-
tion, the two-dimensional test statistic composed of the cumulative partial sum and sample size at stopping is
minimally sufficient for the unknown mean treatment effect θ. We can easily compute the sampling density
of this sufficient statistic (N = n′,S = s) by summing over the r+1 discrete sample paths:
pN,S(n′, s; θ) = ∑
{ j,k: nkj=n′}
pM,S,K( j, s, k; θ). (1.5)
We can also sum over all possible stopping analyses, i.e., all possible combinations of sample paths and
stages, to derive the sample density of the partial sum statistic S:
pS(s; θ) =
h
∑
j=1
pM,S,K( j, s, 0; θ)+
r
∑
k=1
Jk
∑
j=h+1
pM,S,K( j, s, k; θ). (1.6)
The sampling density computations can instead be made on the scale of the sample mean statistic T ≡
θˆ j = 1N j S j. For example, sampling densities of the sample mean statistic are shown in Figure 1.2 for a
two-stage adaptive design derived from an O’Brien and Fleming reference group sequential design, with
a conditional power-based function for modifying the final sample size (see section 3.1 for more design
details). These density functions are compared to those of fixed sample and O’Brien and Fleming group
sequential designs with the same power (90% at θ= ∆) in Figures 1.3 and 1.4.
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Figure 1.2: Probability density function of the sample mean T ≡ θˆ under a pre-specified adaptive design
presuming three different values for the treatment effect θ.
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Figure 1.3: Probability density function of the sample mean T ≡ θˆ under a fixed sample design presuming
three different values for the treatment effect θ.
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Figure 1.4: Probability density function of the sample mean T ≡ θˆ under an O’Brien and Fleming group
sequential design presuming three different values for the treatment effect θ.
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81.5 Operating Characteristics
Because we can write out and numerically evaluate the sampling density of the test statistic (M,T,K), we
can easily compute frequentist operating characteristics. Assume that the boundaries are defined on the scale
of the sample mean T ≡ θˆ. Under a presumed treatment effect θ, the upper and lower stopping probabilities
of a pre-specified adaptive design are:
Pu(θ) =
h
∑
j=1
P(T ≥ d0j ,M = j,K = 0; θ) +
r
∑
k=1
Jk
∑
j=h+1
P(T ≥ dkj ,M = j,K = k; θ)
=
h
∑
j=1
∞∫
d0j
fM,T,K( j, t, 0; θ) dt+
r
∑
k=1
Jk
∑
j=h+1
∞∫
dkj
fM,T,K( j, t, k; θ) dt, (1.7)
Pl(θ) =
h
∑
j=1
P(T ≤ a0j ,M = j,K = 0; θ) +
r
∑
k=1
Jk
∑
j=h+1
P(T ≤ akj,M = j,K = k; θ)
=
h
∑
j=1
a0j∫
−∞
fM,T,K( j, t, 0; θ) dt+
r
∑
k=1
Jk
∑
j=h+1
akj∫
−∞
fM,T,K( j, t, k; θ) dt. (1.8)
Therefore, we can easily compute the type I error α = Pu(θ0) and the power β(∆) = Pu(∆) at a particular
alternative θ = ∆ for such a pre-specified adaptive design, or can choose boundaries (akj, dkj ), k = 0, j =
1, . . . ,h and k = 1, . . . ,r, j = h+1, . . . ,Jk, to satisfy desired levels of type I error and power. In addition, the
expected sample size at an assumed treatment effect θ is
ASN(θ) =
h
∑
j=1
[
P(T ≥ d0j ,M = j,K = 0; θ)+P(T ≤ a0j ,M = j,K = 0; θ)
]
n0j
+
r
∑
k=1
Jk
∑
j=h+1
[
P(T ≥ dkj ,M = j,K = k; θ)+P(T ≤ akj,M = j,K = k; θ)
]
nkj. (1.9)
Since the operating characteristics of such pre-specified adaptive sampling plans are just functions of the op-
erating characteristics of a set of group sequential designs, we can amend existing group sequential software
to carry out these computations. All of our computations were performed using the R package RCTdesign
built from the S-Plus module S+SeqTrial (S+SeqTrial, 2002).
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9Chapter 2
Inference after an Adaptive Hypothesis Test
2.1 Introduction
Confirmatory phase III clinical trials need to produce results that are interpretable, in that sufficiently reliable
and precise inferential statistics can be computed at the end of the trial. This helps ensure that regulatory
agencies approve new treatment indications based on reliable evidence of clinically meaningful benefit to
risk profiles and not simply because of statistical significance. Reliable and precise estimates also allow
regulatory agencies to appropriately label new treatments and clinicians to effectively practice evidence-
based medicine. In its recent draft guidance on adaptive clinical trials (Food and Drug Administration,
2010), the FDA identifies as a principal issue “whether the adaptation process has led to positive study results
that are difficult to interpret irrespective of having control of Type I error.” In addition, this guidance cautions
against the use of designs at the confirmatory stage in which interim modifications to the study design are
not pre-specified “because it is not possible to enumerate the universe from which choices are made.” These
considerations provide motivation to focus on developing and evaluating inferential procedures in the setting
where adaptive sampling plans are completely pre-specified. By investigating an ordering of the outcome
space based on the inversion of conditional error-based adaptive hypothesis tests, we will also be able to
evaluate the behavior of inference in the presence of unplanned modifications to the sampling plan. In
particular, our findings will help quantify the cost of failing to plan ahead in settings where sample size
adaptations, if desired, could realistically be pre-specified at the design stage.
2.2 Exact Confidence Sets and Orderings of the Outcome Space
We construct confidence sets based on the duality of hypothesis testing and confidence interval estimation.
The confidence set consists of all hypothesized values for the parameter θ of interest that would not be
rejected by an appropriately sized hypothesis test given the observed data. We note that these may not
correspond to useful hypothesis tests. If we had been interested in testing a different null hypothesis, we
would have chosen a different sequential design. These hypothetical tests are instead used to identify results
http://biostats.bepress.com/uwbiostat/paper388
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incompatible with the observed data in order to aid in estimation.
Formally, we define equal tailed (1−2α)×100% confidence sets for θ by inverting a family of hypoth-
esis tests with two-sided type I error probability 2α. We could analogously derive two-sided confidence
sets with unequal tail probabilities or one-sided confidence sets. We restrict attention to two-sided confi-
dence sets because these are preferred for most clinical trials, and they are necessary in some settings (e.g.
non-inferiority trials). As in the group sequential setting, we define an acceptance region of “non-extreme”
results for the test statistic (M,T,K) for each possible value of θ:
A(θ,α) = {( j, t,k) : 1−α > P[ (M,T,K)  ( j, t,k); θ ] > α}
where  indicates “greater.” We then use this acceptance region to define a (1−2α)×100% confidence set
as
CSα(M,T,K) = {θ : (M,T,K) ∈ A(θ,α)}.
In order to apply this in practice, however, we need to define “more extreme” by imposing an ordering on
the three-dimensional outcome (sample) space Ω:
Ω = {( j, t,k) : t ∈ S kj ; k = 0, j = 1, . . . ,h and k = 1, . . . ,r, j = h+1, . . . ,Jk}.
The outcome space actually consists of nkj observations on each treatment arm. However, most intuitively
reasonable orderings will rank outcomes only on the basis of information contained in the statistic (M,T,K),
or the minimal sufficient statistic (N,T ). The Neyman-Pearson Lemma indicates that, for a simple alterna-
tive hypothesis H1 : θ= ∆, the most powerful level α test is based on the likelihood ratio statistic. However,
clinical trialists are generally interested in composite alternative hypotheses consisting of a range of plausi-
ble, clinically meaningful treatment effects. Just as in the group sequential setting, the probability density
function for an adaptive design does not have monotone likelihood ratio, so the theory for optimal tests and
confidence intervals (Lehmann, 1959) in the presence of a composite alternative hypothesis does not apply.
Monotone likelihood ratio would imply that, for any arbitrary θ1 < θ2,
pM,T,K( j′, t ′,k′; θ= θ2)
pM,T,K( j′, t ′,k′; θ= θ1)
<
pM,T,K( j, t,k; θ= θ2)
pM,T,K( j, t,k; θ= θ1)
for all ( j′, t ′,k′)< ( j, t,k).
Applying relation 1.4, this corresponds to the following condition:
2nk
′
j′ t
′− (θ1+θ2)nk′j′ < 2nkj t− (θ1+θ2)nkj.
For nk
′
j′ = n
k
j, this is simply an ordering by the observed partial sum statistic. However, when n
k′
j′ 6= nkj, the
ordering depends upon θ1 and θ2. Thus, we cannot find monotone likelihood ratio under any ordering of the
outcome space Ω.
Because there is no clear best choice of an ordering for the outcome space, it is useful to evaluate the
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behavior of a variety of different orderings with respect to a range of important properties. We note that the
consideration of different orderings of the outcome space to carry out statistical inference is not something
unique to the setting of a sequential clinical trial. We frequently choose between the likelihood ratio, Wald,
and score statistics, which impose different orderings on the outcome space, to carry out hypothesis tests
and compute confidence intervals.
In the group sequential setting, several intuitively reasonable orderings of the outcome space have been
used to carry out inference - the most widely studied and implemented orderings are based on the stage at
stopping, the sample mean, and the likelihood ratio test statistic. We extend these three group sequential
orderings to the setting of a pre-specified adaptive design. We also consider confidence intervals derived by
inverting adaptive hypothesis tests based on preserving the conditional type I error, as proposed by Brannath,
Mehta, and Posch (2009).
Assume that continuation and stopping sets have been defined on the scale of the sample mean statistic
T ≡ θˆ. Consider the following orderings:
• Sample mean ordering (SM). Outcomes are ordered according to the value of the maximum likelihood
estimate, which is the sample mean T . In the setting of a pre-specified adaptive test as described in
chapter 1, this ordering is imposed by the condition
( j′, t ′,k′) ( j, t,k) if t ′ > t. (2.1)
• Signed likelihood ratio ordering (LR). Outcomes are ordered according to the value of the signed
likelihood ratio test statistic against a particular hypothesized parameter value θ′:
( j′, t ′,k′)θ′ ( j, t,k) if sign(t ′−θ′) pM,T,K( j
′, t ′,k′; θ= t ′)
pM,T,K( j′, t ′,k′; θ= θ′)
> sign(t−θ′) pM,T,K( j, t,k; θ= t)
pM,T,K( j, t,k; θ= θ′)
.
Recalling relation 1.4, we can show that
pM,T,K( j′, t ′,k′; θ= t ′)
pM,T,K( j′, t ′,k′; θ= θ′)
∝ exp
(
nk
′
j′
4σ2
(t ′−θ′)2
)
.
Therefore, it is easy to see that the signed likelihood ratio ordering simplifies to
( j′, t ′,k′)θ′ ( j, t,k) if
√
nk′j′(t
′−θ′)>
√
nkj(t−θ′). (2.2)
We note that there is a different likelihood ratio ordering for each hypothesized value of the parameter
of interest.
• Stage-wise orderings. Outcomes are ordered according to the “stage” at which the study stops. In
the group sequential setting, the rank of the sample sizes is equivalent to the rank of the analysis
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times, so there is only one “analysis time” or “stage-wise” ordering. In the adaptive setting, this is
not necessarily the case, so there are an infinite number of ways to extend and impose a stage-wise
ordering. We consider the following:
– Analysis time + Z statistic ordering (Z). Outcomes are ordered according to the analysis time at
which the study stops, with ties broken by the value of the cumulative Z statistic.
( j′, t ′,k′) ( j, t,k) if

j′ < j and t ′ ∈ S k′(1)j′
j′ > j and t ∈ S k′(0)j′
j′ = j and z′ > z
. (2.3)
– Analysis time + re-weighted Z statistic ordering (Zw). Outcomes are ordered according to the
analysis time at which the study stops, with ties broken by the value of a re-weighted cumulative
Z statistic Zw. For a design in which the adaptation occurs at the penultimate analysis (J = Jk =
h+1, for k = 1, . . . ,r), we define
Zw =
{
Z j if j ≤ h
∑Jj=1 w j Z∗j if j = J
with pre-specified weights {w j, j = 1, . . . ,J} such that ∑Jj=1 w2j = 1. We consider the Cui, Hung,
and Wang statistic (1999), which maintains the same weights for the incremental normalized
statistics Z∗j as under the original fixed sample or group sequential design. For example, with
only one interim analysis at one half the originally planned final sample size, w1 = w2 =
√
1/2.
This re-weighted Z statistic is then used to extend a stage-wise ordering of the outcome space.
If an adaptation has been performed, the ordering depends not only on the sufficient statistic
(M,T,K), but additionally on the value of the interim estimate of treatment effect (this is needed
to compute Zw):
( j′, t ′,k′,z′w) ( j, t,k,zw) if

j′ < j and t ′ ∈ S k′(1)j′
j′ > j and t ∈ S k′(0)j′
j′ = j and z′w > zw
. (2.4)
In considering the two above orderings, we note that two equivalent analysis times j′ = j could
correspond to vastly different sample sizes nk
′
j′ 6= nkj for k′ 6= k under an adaptive design.
– Statistical Information Ordering (N). Outcomes are ordered according to the amount of statisti-
cal information that has been accrued at the time the study stops, with ties broken by the value of
the sample mean. In the setting of approximately normally distributed incremental partial sum
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statistics, this is simply an ordering by the sample size at stopping:
( j′, t ′,k′) ( j, t,k) if

nk
′
j′ < n
k
j and t
′ ∈ S k′(1)j′
nk
′
j′ > n
k
j and t ∈ S k
′(0)
j′
nk
′
j′ = n
k
j and t
′ > t
. (2.5)
In considering this ordering, we note that two equivalent sample sizes nk
′
j′ = n
k
j may correspond
to vastly different analysis times j′ 6= j for k′ 6= k under an adaptive design.
• BMP Conditional Error Ordering (BMP). Defined by Brannath, Mehta, and Posch (2009), outcomes
are ordered according to the level of significance for which a conditional error-based one-sided adap-
tive hypothesis test would be rejected, in which incremental P-values are computed based on the group
sequential stage-wise ordering. Like the likelihood ratio ordering, this procedure depends on the hy-
pothesized value of θ. In addition, if an adaptation has been performed, the BMP ordering depends
not only on the sufficient statistic (M,T,K), but additionally on the value of the interim estimate of
treatment effect. It also depends on the specification of a reference group sequential design (GSD) for
conditional type I error computations. Formally, for testing against one-sided greater alternatives,
( j′, t ′,k′, t ′h)θ′,GSD ( j, t,k, th) if µ( j′, t ′,k′, t ′h; θ′,GSD) < µ( j, t,k, th; θ′,GSD) (2.6)
where the significance level µ is defined as follows. If the trial stops before an adaptation has oc-
curred, µ is simply the upper one-sided P-value under the stage-wise ordering of the reference GSD.
Otherwise, for an arbitrary µ′, we would first find the 1−µ′ quantile of the original GSD, under θ= θ′
and the stage-wise ordering, in order to define a conceptual new level µ′ group sequential hypothe-
sis test of H0 : θ = θ′ against the alternative θ > θ′. We compute the conditional type I error of this
group sequential hypothesis test, i.e., the probability under H0, conditional of having observed th at the
adaptation analysis, of going on to reject the null hypothesis. We then calculate the upper P-value for
the observed post-adaptation data under the stage-wise ordering of the adaptively chosen secondary
design. If this P-value is less than the conditional type I error, then the null hypothesis H0 : θ = θ′
would have been rejected by a level µ′ conditional error-based adaptive hypothesis test. µ is defined
as the smallest µ′ for which H0 would have been rejected given the observed data.
This ordering was described in a more intuitive way in a recently submitted manuscript by Gao, Liu,
and Mehta (2012). µ is computed as the stage-wise P-value of the “backward image,” in the outcome
space of the original group sequential design, of the observed test statistic (M,T,K) = ( j, t,k). The
“backward image” is simply defined as the outcome ( jbw, tbw) for which the stage-wise P-value for
testing H0 : θ = θ′ under the original GSD, conditional on the interim estimate th, is equal to the
analogous conditional stage-wise P-value for the observed statistic under the adaptively chosen group
sequential path. If d0i , i = 1, . . . ,J0, are the superiority boundaries under the original GSD, we find
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( jbw, tbw) such that
Pθ′ [ (∪ jbw−1i=h+1 (Ti > d0i ) ∪ Tjbw > tbw ) |Th = th,GSD ] =Pθ′ [ (∪ j−1i=h+1 (Ti > dki ) ∪ Tj > t ) |Th = th,GSDk ]
where GSDk indicates the adaptively chosen group sequential path. Thus, every outcome under every
potential adaptively chosen path (for which the conditional type I error would have been preserved) is
mapped to a single outcome in the sample space of the original group sequential design.
One important characteristic of this ordering is that it does not depend on the sampling plan we would
have followed had we observed different interim data. Brannath, Mehta, and Posch (2009) formally
derive and evaluate only one-sided confidence sets under this ordering. However, as they briefly note
in their discussion and is formalized in the recently submitted paper by Gao, Liu, and Mehta (2012),
this method can be easily extended to two-sided confidence sets.
For any one of the above orderings O = o and an observed test statistic (M,T,K) = ( j, t,k), we can
define a (1−2α)×100% confidence set
CSαo ( j, t,k) = {θ : 1−α > P[ (M,T,K)o ( j, t,k);θ ] > α}. (2.7)
Note that we need more information than is contained in the statistic (M,T,K) to apply some of the pre-
viously described orderings. There is no guarantee that this confidence set will be a true interval. True
intervals are guaranteed only if the sequential test statistic (M,T,K) is stochastically ordered in θ under the
ordering O = o, i.e., if P[ (M,T,K) o ( j, t,k) ; θ ] is an increasing function of θ for each ( j, t,k) ∈ Ω. We
are able to prove stochastic ordering in θ for the sample mean ordering (see Appendix A) by generalizing
Emerson’s proof (1988) in the group sequential setting. Brannath, Mehta, and Posch (2009) demonstrate
that stochastic ordering does not hold for some adaptive designs under the conditional error-based ordering.
We have been unable to prove or find violations of stochastic ordering for the other orderings described
above. In all numerical investigations, we compute confidence intervals (θL,θU) through an iterative search
for parameter values θL and θU such that
P[ (M,T,K) o ( j, t,k); θL ] = α,
P[ (M,T,K) o ( j, t,k); θU ] = 1−α. (2.8)
We can only guarantee theoretically that the resulting intervals under the sample mean ordering will have
exact (1−2α)×100% coverage. If stochastic ordering does not hold for the other orderings, it is possible
that confidence intervals derived in this way have true coverage below or above the nominal level. One
could also compute confidence intervals based on the infimum and supremum of the confidence set defined
in (2.7) in order to ensure conservative coverage. However, observed confidence intervals (θL,θU) derived
via (2.8) have had exact coverage, within simulation error, under all orderings and for all of our numerical
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investigations (see results in the next chapter). These findings suggest that any deviations of the exact
confidence sets defined in (2.7) from true intervals for the range of adaptive designs we have considered are
negligible, if they exist at all.
2.3 Point Estimates and P-values
We extend several methods for point estimation following a group sequential trial to the setting of a pre-
specified adaptive sampling plan. Some of these estimates rely on the specification of an ordering of the
outcome space. We define the following point estimates for the parameter θ of interest given the observed
test statistic (M,T,K) = ( j, t,k):
• Sample Mean. The sample mean θˆ≡ T is the maximum likelihood estimate and is independent of an
imposed ordering of the outcome space:
θˆ= XA−XB = t. (2.9)
• Bias adjusted mean. The bias adjusted mean (BAM), proposed by Whitehead (1986) in the group
sequential setting, is also independent of an imposed ordering and can be easily extended to the
setting of a pre-specified adaptive design. The BAM is defined as the parameter value θˇ satisfying
ET [T ; θˇ ] = t. (2.10)
• Median-unbiased estimates. A median-unbiased estimate (MUE) is defined as the parameter value θ˜o
that, under a particular ordering of the outcome space O = o, satisfies
P[ (M,T,K)o ( j, t,k); θ˜o ] = 12 . (2.11)
We compute median-unbiased estimates based on the sample mean, likelihood ratio, stage-wise (anal-
ysis time + Z statistic, analysis time + Zw statistic, statistical information), and conditional error
orderings: θ˜SM, θ˜LR, θ˜Z , θ˜Zw, θ˜N , and θ˜BMP, respectively.
A particular ordering of the outcome space can also be used to compute a P-value. For the null hypoth-
esis H0 : θ= θ0, we compute the upper one-sided P-value under an imposed ordering as
p-valueo = P[ (M,T,K)o ( j, t,k); θ0 ]. (2.12)
We could analogously define two-sided and lower one-sided P-values under an imposed ordering of the
outcome space.
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2.4 Example Inference
Consider the optimal pre-specified symmetric two-stage adaptive designs described in section 4.1 of our
recent paper (Levin, Emerson, & Emerson, 2012) with type I error α= 0.025 at θ= 0 and power β= 0.975
at θ= ∆= 3.92. Table 2.1 displays different point and interval estimates at the stopping boundaries for the
optimal design with eight possible sample paths (r = 8). Only confidence intervals based on the sample
mean ordering have the property of spanning exactly from the null to the alternative hypothesis when the
estimate of treatment effect is on the boundary at the final analysis, regardless of the adaptively chosen group
sequential path. This desirable behavior is observed because the symmetry of the design implies that the
boundaries dk2,k = 1, . . . ,8, are constant on the sample mean scale. We could instead select final boundaries
to ensure that confidence intervals based on some other ordering exactly exclude the null hypothesis when
the estimate is on the boundary at the final analysis. We will discuss in more detail the issue of choosing
boundaries to ensure consistency between confidence intervals and hypothesis tests in the following sections.
Also of note in Table 2.1, when the trial stops at the final analysis, point estimates and confidence intervals
based on the Zw and BMP orderings depend on the estimate of treatment effect at the adaptation analysis.
We display estimates for the smallest and largest possible observed interim estimates through each path.
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2.5 Optimality Criteria for the Reliability and Precision of Inference
After carefully selecting a sequential statistical sampling plan, consisting of stopping and adaptation rules,
clinical trial investigators must also choose a procedure for carrying out inference at the end of the study.
For a given sampling plan satisfying the scientific constraints of a particular clinical trial design setting, it
is desirable to choose inferential procedures with the best achievable reliability and precision. It is common
statistical practice to evaluate candidate methods, theoretically and/or numerically, and then to choose the
estimates with superior small or large sample properties. Many of the typical criteria for evaluating fixed
sample estimates remain important in the sequential setting, but additional unique properties become of
interest as well. Emerson (1988), Jennison and Turnbull (2000), and others (Tsiatis, Rosner, & Mehta,
1984; Chang & O’Brien, 1986; Rosner & Tsiatis, 1988; Chang, 1989; Emerson & Fleming, 1990; Chang,
Gould, & Snapinn, 1995; Gillen & Emerson, 2005) have enumerated desirable properties of confidence sets,
point estimates, and P-values after a group sequential test, and these optimality criteria readily generalize to
the adaptive setting.
As mentioned previously, it is preferable that stochastic ordering holds, so that exact confidence sets
are guaranteed to be true intervals. Alternatively, we would hope to demonstrate that confidence intervals
computed via (2.8) have approximately exact coverage for all practical designs. This would suggest that any
deviations from stochastic ordering, if they exist at all, cause negligible departures from true intervals. In
addition, it is desirable for confidence intervals and P-values to agree with the hypothesis test, a property
which we will refer to as “consistency.” More specifically, consistency means that P-values are less than
the specified significance level and confidence intervals exclude the null hypothesis if and only if the null
hypothesis is rejected. Consistency under an imposed ordering O= o can be guaranteed by choosing critical
boundaries akj and d
k
j such that d
k
j o akj for all k and j, i.e., all superiority outcomes are “greater” under
that ordering than all non-superiority outcomes. Ensuring that consistency is satisfied results in different
boundaries under different orderings of the outcome space and subsequently impacts the power curve of the
design.
As with a fixed sample or group sequential design, we also want confidence intervals to be as precise
as possible. The amount of statistical information available at the time of stopping is a random variable
under a sequential sampling plan, resulting in confidence intervals of varying lengths. Therefore, one rea-
sonable measure of precision is the expected confidence interval length under different presumed values of
θ, with shorter intervals to be desired. Another relevant criterion is the probability of P-values falling below
important thresholds, such as 0.001 and 0.000625. We are interested in these power functions because the
probability of obtaining very low P-values is an important consideration when a single confirmatory trial
may be used as a “pivotal” study. The FDA occasionally approves a new treatment indication based on a
single pivotal adequate and well-controlled confirmatory trial that has the statistical strength of evidence
close or equal to that of two positive independent studies (e.g. 0.0252 = 0.000625). Finally, we prefer point
estimates with the best achievable accuracy and precision. Standard measures include bias, variance, and
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mean squared error. Additionally, we may desire confidence intervals to include those point estimates found
to have the best behavior.
In the group sequential setting, some investigators (e.g., Jennison & Turnbull, 2000) have stated a pref-
erence for the stage-wise ordering primarily because corresponding estimates and P-values depend only on
the observed data and the stopping rules of analyses that have already been carried out. This is desirable
because the interim analyses of most clinical trials occur at unpredictable information sequences, as Data
Monitoring Committee (DMC) meetings need to be scheduled in advance. We note that there are alternative
approaches to accommodate a flexible schedule of analyses in the group sequential setting, such as the use
of constrained boundaries (Burrington & Emerson, 2003). Importantly, this criterion does not apply to the
general setting of a pre-specified adaptive design, because none of the orderings we have described depend
only on the analyses that have been conducted. The stage-wise orderings we have considered depend on
the sampling plan under alternative sample paths because the trial may have stopped at an earlier stage or
smaller sample size had a different interim estimate of treatment effect been observed. Similarly, the BMP
approach depends upon the specification of an exact sampling plan for the reference group sequential design
used to compute the conditional error. We need to know what would have been the future sampling plan in
the absence of an adaptation.
Because the sampling density does not have monotone likelihood ratio under any ordering of the out-
come space, we would not expect uniformly optimal tests or estimation procedures. Instead, as in the group
sequential setting, it is likely that the relative performance of different estimation procedures depends on
both the adaptive sampling plan and the true value of treatment effect θ. Estimates must be derived in an
iterative search by numerically integrating the sampling density. This makes it extremely difficult to come
up with general analytic results comparing different estimation procedures with respect to any of the im-
portant properties assessing reliability and precision. Thus, we use numerical investigations to rigorously
investigate the behavior of the different orderings of the outcome space and inferential methods. In the next
chapter, we introduce and implement a comparison framework to evaluate estimation methods through the
extensive simulation of clinical trials across a wide range of different adaptive designs.
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Chapter 3
Comparing Different Inferential Procedures
3.1 Comparison Framework
Consider the simple and generalizable RCT design setting described in section 1.2, where it is desired to
test the null hypothesis H0 : θ= θ0 = 0 against the one-sided alternative θ> 0 with type I error probability
α = 0.025 and power β at θ = ∆. Without loss of generality, we let σ2 = 0.5, so that the alternative ∆
can be interpreted as the number of sampling unit standard deviations detected with power β. We consider
the class of pre-specified adaptive designs described in section 1.3. In order to cover a broad spectrum of
adaptive designs in our evaluation of the reliability and precision of inference under different orderings of
the outcome space, we allow the following design parameters to vary:
• The degree of early conservatism. We derive adaptive designs from reference group sequential designs
with either O’Brien and Fleming (1979) or Pocock (1977) stopping boundaries.
• The power. We consider adaptive designs for which θ = ∆ represents the alternative hypothesis de-
tected with power β equal to 0.80, 0.90, or 0.975.
• The maximum number of analyses J. We start with group sequential designs having a maximum of
two or four analyses, and consider adaptations to sample paths with up to eight analyses.
• The timing of the adaptation. We consider adaptation analyses occurring between 25% and 75% of
the original maximal sample size, and as early as the first and as late as the third interim analysis.
• The maximum allowable sample size NJmax . We consider designs with adaptations allowing up to
a 25%, 50%, 75%, or 100% increase in the maximal sample size of the original group sequential
design. We present results only for sampling plans with 50% and 100% potential increases in the
maximal sample size because these two classes of designs fully capture the trends we have observed
when the maximum allowable sample size is varied.
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• The rule for determining the final sample size. We derive adaptive designs with two different classes
of functions of the interim estimate of treatment used to adaptively determine the maximal sample
size. First, we consider the following quadratic function of the sample mean T = t observed at the
adaptation analysis: NJ(t) = NJmax − a(t − d
0
h−a0h
2 )
2, where a is chosen to satisfy the desired power
β. The use of such a symmetric function, with the maximal sample size increase at the midpoint of
continuation region of the original GSD, approximates the sample size rules that we (Levin et al.,
2012) and others (Posch, Bauer, & Brannath, 2003; Jennison & Turnbull, 2006) have observed to be
nearly optimal in investigations of the efficiency of different adaptive hypothesis tests. Second, we
consider adaptation rules in which the final sample size NJ(t) is determined in order to maintain the
conditional power (CP) at a pre-specified desired level, presuming the interim estimate of treatment
effect is the truth (θ = t). We set this level at the the unconditional power at θ = ∆ of the original
group sequential design. Although we do not recommend the use of conditional power-based sample
size functions, they are frequently proposed in the literature (e.g., Proschan & Hunsberger, 1995;
Wassmer, 1998; Cui et al., 1999; Denne, 2001; Brannath, Posch, & Bauer, 2002; Brannath, Ko¨nig, &
Bauer, 2006; Gao, Ware, & Mehta, 2008; Mehta & Pocock, 2011). Thus, it is important to evaluate
the behavior of inference in the presence of such sampling plans. Figure 3.1 displays an example of
symmetric and CP-based sample size modification rules. For both symmetric and conditional power-
based sample size functions, we impose the restriction of no greater than a 25% decrease in the final
sample size of the original group sequential design. We also require that interim analyses occur after
the accrual of at least 20% of the number of participants in the previous stage. We imposed these
restrictions to keep designs as realistic as possible: drastic decreases in an originally planned sample
size are typically not desirable or practical, and scheduling Data Monitoring Committee meetings to
carry out interim analyses occurring very close together (in terms of calendar time or sample size) is
not logistically or economically reasonable.
We consider adaptive hypothesis tests with r = 10 equally sized continuation regions and corresponding
potential sample paths because our research has demonstrated that including more than a few regions leads
to negligible efficiency gains (Levin et al., 2012). Increasing or decreasing r has negligible impact on the
relative behavior of inferential methods. The final sample size nkJ to which the trial will proceed if the interim
estimate of treatment effect falls in continuation region Ckh is determined by the sample size function NJ(t)
evaluated at the midpoint of the continuation region, for k = 1, . . . ,r.
The final design parameters that must be determined are the critical superiority boundaries akJ = d
k
J at the
final analysis of sample paths k = 1, . . . ,r. As previously mentioned, it is desirable for confidence intervals
and P-values to agree with the hypothesis test, i.e., confidence intervals to exclude θ0 and P-values to fall
below 0.025 if and only if H0 is rejected. Consistency under an imposed ordering O = o can be guaranteed
by choosing critical boundaries akj and d
k
j such that d
k
j o akj for all k and j, i.e., all superiority outcomes
are “greater” under that ordering than all non-superiority outcomes. In many other statistical settings, it
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Figure 3.1: The adaptively chosen maximal sample size N2 for two-stage adaptive designs, based on sym-
metric or conditional power-based (CP) functions of the interim estimate of treatment effect, subject to the
restriction of a 100% maximal increase relative to the final sample size of the reference O’Brien and Fleming
group sequential design (GSD).
is common (often simply due to software defaults) to compute confidence intervals and P-values under
different orderings of the outcome space. For example, proportional hazards inference frequently involves
testing with the score (log-rank) statistic but interval estimation based on the Wald statistic. While it is
probably desirable to always use the same ordering for testing and estimation, this issue is not typically
a concern in settings where the probability of disagreement is quite low. However, in the setting of an
adaptive sampling plan, there can be a very high and clearly unacceptable degree of inconsistency. For
example, Figure 3.2 illustrates the potential implications of carrying out conditional error-based hypothesis
tests while computing CIs based on the sample mean or likelihood ratio orderings. The probabilities that
confidence intervals disagree with the test are frequently near 5% and can be as high as 15% for particular
designs and treatment effects. In the adaptive setting, it is thus very important to use the same ordering of
the outcome space to carry out tests as to compute P-values and CIs.
In our design comparison framework, we therefore choose boundaries akJ = d
k
J in order to ensure (near)
consistency between the adaptive hypothesis test and inference under a particular ordering of the outcome
space. The conditional error and Zw orderings depend not only on the observed statistic (M,T,K) = ( j, t,k),
but also on the interim estimate Th = th. Therefore, a design would require a unique dJ for each potential
value of ( j, t,k, th) in order to guarantee consistency between the hypothesis test and confidence interval.
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Figure 3.2: Probability that confidence intervals under different orderings of the outcome space are inconsis-
tent with conditional error-based hypothesis tests, for a pre-specified two-stage adaptive tests derived from
an O’Brien and Fleming group sequential design. The sample size function is symmetric about the midpoint
of the continuation region at the adaptation analysis and subject to the restriction of a 100% maximal in-
crease relative to the final sample size of the reference group sequential design. Probabilities are displayed
for the sample mean (SM), likelihood ratio (LR), and conditional error (BMP) orderings.
However, with r = 10 sample paths and corresponding choices of the final superiority boundary, we have
not yet observed the probability of disagreement between test and CI to surpass 1% for any combination of
design and treatment effect. If this is still considered unacceptable, one could easily increase r to ensure neg-
ligible disagreement without materially affecting the precision of inference, although increasing the number
of paths has potential undesirable effects on maintaining confidentiality (Levin et al., 2012). Alternatively,
one could simply base the decision at the final analysis on the confidence interval under a prospectively
chosen ordering of the outcome space. In other words, the null hypothesis is rejected at the final analysis if
and only if the lower bound of the confidence interval excludes θ0. In any case, care needs to be taken to
ensure that CIs, P-values, and hypothesis tests agree at a level that is satisfactory.
We illustrate our comparison framework using a simple example for which results on the reliability and
precision of inference will be presented in the following sections. Consider a reference O’Brien and Fleming
group sequential design (GSD) with two equally spaced analyses and 90% power at θ = ∆. The GSD has
analyses at 51% and 101% of the fixed sample size n needed to achieve the same power. We derive an
adaptive sampling plan from the GSD that allows up to a 100% increase in the maximal sample size, so
that NJmax = 2 ∗ 1.01n = 2.02n. We divide the continuation region of the GSD at the first analysis into ten
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equally sized regions Ck1,k = 1, . . . ,10, and determine each corresponding final sample size n
k
2 by evaluating
the quadratic function NJ(t) = 2.02n− 1.627(t − 1.96)2 at the region’s midpoint (a = 1.627 was chosen
so that the adaptive test attains 90% power at θ = ∆). We consider several different adaptive hypothesis
tests, for which boundaries ak2 = d
k
2,k = 1, . . . ,10, are chosen so that observed statistics on the boundaries
at the final analysis are equally “extreme” under the sample mean (SM), likelihood ratio (LR), statistical
information N, analysis time + Z statistic (Z), analysis time + re-weighted Z statistic (Zw), or conditional
error (BMP) orderings of the outcome space. All tests have the same sample size modification rule and thus
the same average sample size at all θs. However, the tests based on different orderings of the outcome space
have contrasting functions for the final superiority boundary and thus have slightly different power curves.
Figure 3.3 presents superiority boundaries at the final analysis and de-trended power curves under a few
orderings of the outcome space. This is just one example selected from the wide range of designs that will
be considered in the following sections. Power differences in Figure 3.3 are indicative of the general trends
observed for the adaptive designs we have considered: likelihood ratio and conditional error ordering-based
hypothesis tests tend to lead to greater power at small treatment effects, while sampling mean ordering-based
testing produces higher power at more extreme effects.
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Figure 3.3: The (a) final critical boundary d2, as a function of the interim estimate of treatment effect, and (b)
power differences, as a function of the true treatment effect (and of power under the sample mean ordering),
for two-stage pre-specified adaptive tests derived from an O’Brien and Fleming group sequential design. The
sample size function is symmetric about the midpoint of the continuation region at the adaptation analysis
and subject to the restriction of no greater than a 100% maximal increase in the sample size. Quantities are
displayed for adaptive tests under different orderings of the outcome space. Power is subtracted from power
under the sample mean ordering.
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We use this extensive design comparison framework to evaluate the relative behavior of different esti-
mation procedures with respect to the characteristics described in section 2.5 that assess the reliability and
precision of inference. We do not claim that all of the adaptive designs considered in the following sections
would potentially be advocated in realistic RCT settings. The purpose of the design framework is to allow
the investigation of different inferential methods across a broad rather than narrow range of sampling plans.
We perform numerical investigations based on 10,000 simulations under each of a wide range of θs for each
adaptive design. We plot the properties of estimates against the power of the test to detect the hypothesized
treatment effect (rather than against θ itself) so that results can be more easily generalized to trials with
different parameters of interest and/or operating characteristics. We present the relative behavior of point
estimates as compared to the bias adjusted mean, and the relative behavior of interval estimates as compared
to sample mean-based confidence intervals, in order to facilitate conclusions about relative performance.
3.2 Eliminating Inferential Methods
Our numerical investigations have demonstrated that a few of the orderings described in section 2.2 exhibit
nearly uniformly inferior behavior with respect to all of the inferential properties considered. We present
results indicative of the poor behavior of the stage-wise + Z-statistic (Z), stage-wise + re-weighted Z-statistic
(Zw), and statistical information (N) orderings, relative to the sample mean (SM), likelihood ratio (LR), and
conditional error (BMP) orderings. Figures 3.4 through 3.7 compare the mean squared error of point esti-
mates and expected length of confidence intervals for two-stage adaptive tests derived from either O’Brien
and Fleming or Pocock group sequential designs, with a few different rules governing modification of the
final sample size. These results demonstrate that the SM, LR, and BMP orderings tend to result in point
estimates with lower MSE and confidence intervals of shorter average length than the other three order-
ings. The general trends evident in these comparisons were observed across a wide range of other adaptive
designs and inferential properties considered. We note that estimates based on the BMP ordering display
similar behavior to those based on the Z and Zw orderings for certain designs and criteria. However, the
BMP ordering behaves much better in some cases, and has the added advantage of conditioning only on
the chosen sample path (discussed further in 3.6). We therefore present results for only the sample mean,
likelihood ratio, and conditional error orderings in the more rigorous numerical investigations to follow in
order to facilitate the presentation and interpretation of our findings.
Figures 3.4 and 3.6 also present the MSE of the maximum likelihood estimate relative to competing
point estimates. We have observed the MLE to have substantially higher bias than many other estimates
at all but intermediate treatment effects, and considerably higher mean squared error (up to ∼ 40% higher)
across nearly all designs and treatments effects considered. Our in-depth discussion of the reliability and
precision of competing point estimates in the next few sections will therefore focus on comparisons of the
SM, LR, and BMP median-unbiased estimates, and the bias adjusted mean.
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(a) Symmetric NJ function, up to 50% Increase
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(c) CP-based NJ function, up to 50% Increase
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(d) CP-based NJ function, up to 100% Increase
Figure 3.4: Mean squared error of median-unbiased estimates (MUEs) under different orderings of the
outcome space, as a proportion of the mean squared error of the bias adjusted mean (BAM), for pre-specified
two-stage adaptive tests derived from an O’Brien and Fleming group sequential design. The sample size
function is either symmetric about the midpoint of the continuation region at the adaptation analysis or
based on maintaining conditional power (CP) at 90%, and is subject to the restriction of either a 50% or
100% maximal increase relative to the final sample size of the reference group sequential design.
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(d) CP-based NJ function, up to 100% Increase
Figure 3.5: Expected length of different confidence intervals, as a proportion of the expected length of the
confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive tests derived
from an O’Brien and Fleming group sequential design. The sample size function is either symmetric about
the midpoint of the continuation region at the adaptation analysis or based on maintaining conditional power
(CP) at 90%, and is subject to the restriction of either a 50% or 100% maximal increase relative to the final
sample size of the reference group sequential design.
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(d) CP-based NJ function, up to 100% Increase
Figure 3.6: Mean squared error of different point estimates, as a proportion of the mean squared error of
the bias adjusted mean, for pre-specified two-stage adaptive tests derived from a Pocock group sequential
design. The sample size function is either symmetric about the midpoint of the continuation region at the
adaptation analysis or based on maintaining conditional power (CP) at 90%, and is subject to the restriction
of either a 50% or 100% maximal increase relative to the final sample size of the reference group sequential
design.
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Figure 3.7: Expected length of different confidence intervals, as a proportion of the expected length of the
confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive tests derived
from a Pocock group sequential design. The sample size function is either symmetric about the midpoint of
the continuation region at the adaptation analysis or based on maintaining conditional power (CP) at 90%,
and is subject to the restriction of either a 50% or 100% maximal increase relative to the final sample size
of the reference group sequential design.
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3.3 Comparisons for Two-stage Adaptive Designs
3.3.1 Confidence Intervals
Given that stochastic ordering may not hold under the likelihood ratio and conditional error orderings for
certain adaptive designs, we would like to verify that confidence intervals derived via (2.8) still have ap-
proximately exact coverage probabilities. Table 3.1 displays the observed coverage for a range of two-stage
adaptive designs. Similar results were observed when additional design parameters were varied. With
10,000 replications and 95% nominal coverage, the standard error of the simulated coverage probability is
0.0022. All simulated coverage probabilities in Table 3.1, except those for the naive fixed sample CIs, fall
within three standard errors of 0.95. Our results suggest that confidence interval coverage is approximately
exact under the SM, LR, and BMP orderings for the range of designs considered.
Table 3.1: Simulated Coverage of 95% Confidence Intervals at Selected Power Points for a Range of Two-
stage Adaptive Tests
OF Reference GSD Pocock Reference GSD
Power Naive SM LR BMP Naive SM LR BMP
Symmetric NJ function, up to 50% Increase
0.025 0.9442 0.9455 0.9449 0.9462 0.9425 0.9484 0.9485 0.9481
0.500 0.9314 0.9507 0.9488 0.9507 0.9458 0.9507 0.9504 0.9507
0.900 0.9402 0.9493 0.9478 0.9476 0.9350 0.9465 0.9467 0.9466
Symmetric NJ function, up to 100% Increase
0.025 0.9495 0.9487 0.9496 0.9493 0.9457 0.9484 0.9501 0.9496
0.500 0.9258 0.9467 0.9473 0.9466 0.9405 0.9465 0.9455 0.9466
0.900 0.9415 0.9505 0.9506 0.9511 0.9372 0.9498 0.9482 0.9501
CP-based NJ function, up to 50% Increase
0.025 0.9403 0.9455 0.9460 0.9461 0.9490 0.9530 0.9531 0.9530
0.500 0.9265 0.9512 0.9486 0.9507 0.9367 0.9466 0.9454 0.9468
0.900 0.9360 0.9480 0.9486 0.9469 0.9392 0.9513 0.9494 0.9513
CP-based NJ function, up to 100% Increase
0.025 0.9428 0.9494 0.9497 0.9494 0.9441 0.9502 0.9508 0.9505
0.500 0.9181 0.9462 0.9469 0.9466 0.9355 0.9461 0.9476 0.9462
0.900 0.9291 0.9501 0.9501 0.9501 0.9365 0.9494 0.9489 0.9496
As discussed in section 2.5, we would like point and interval estimates following a hypothesis test to
be as precise as possible. An important measure of the precision of confidence intervals is the expected
length. The relative behavior of confidence intervals may depend on the adaptive sampling plan and the
presumed treatment effect. Figures 3.8 and 3.9 present average lengths of CIs based on the sample mean,
likelihood ratio, and conditional error orderings for two-stage adaptive designs derived from O’Brien and
Fleming and Pocock group sequential designs, respectively, with varying functions for and restrictions on the
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maximal increase in the final sample size. These results demonstrate that the likelihood ratio ordering tends
to produce approximately 1% to 10% shorter confidence intervals than the sample mean and conditional
error (BMP) orderings, depending on the adaptive sampling plan and presumed treatment effect. The margin
of superiority increases with the potential sample size inflation and is slightly greater for CP-based than
symmetric sample size modification rules. The sample mean ordering produces approximately 1− 3%
shorter expected confidence interval lengths than the BMP ordering for adaptive tests derived from Pocock
group sequential designs, but these two orderings yield similar expected CI lengths when the reference
design has more conservative O’Brien and Fleming early stopping boundaries.
Because Brannath, Mehta, and Posch (2009) formally derive only one-sided confidence intervals, we
also compare expected CI “half-lengths,” defined as the distance between the lower CI bound and the
median-unbiased estimate under a particular ordering of the outcome space (for a hypothesis test against
a greater one-sided alternative). Figures 3.10 and 3.11 display similar trends for this criterion as described
above for the expected lengths of the full intervals. It is also important to note that we have observed
confidence intervals based on the sample mean, likelihood ratio, and conditional error orderings to always
contain the bias adjusted mean. This is desirable because results in section 3.3.2 will demonstrate that
the bias adjusted mean tends to be both more accurate and precise than the other point estimates we have
considered.
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Figure 3.8: Expected length of different confidence intervals, as a proportion of the expected length of the
confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive tests derived
from an O’Brien and Fleming group sequential design. The sample size function is either symmetric about
the midpoint of the continuation region at the adaptation analysis or based on maintaining conditional power
(CP) at 90%, and is subject to the restriction of either a 50% or 100% maximal increase relative to the final
sample size of the reference group sequential design.
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Figure 3.9: Expected length of different confidence intervals, as a proportion of the expected length of the
confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive tests derived
from a Pocock group sequential design. The sample size function is either symmetric about the midpoint of
the continuation region at the adaptation analysis or based on maintaining conditional power (CP) at 90%,
and is subject to the restriction of either a 50% or 100% maximal increase relative to the final sample size
of the reference group sequential design.
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(a) Symmetric NJ function, up to 50% Increase
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(c) CP-based NJ function, up to 50% Increase
0.0 0.2 0.4 0.6 0.8 1.0
0.
92
0.
94
0.
96
0.
98
1.
00
1.
02
1.
04
Power
Pr
op
.
 
of
 S
M 
Ex
pe
cte
d C
I H
alf
 Le
ng
th
SM
LR
BMP
(d) CP-based NJ function, up to 100% Increase
Figure 3.10: Expected half length of different confidence intervals, as a proportion of the expected half
length of the confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive
tests derived from an O’Brien and Fleming group sequential design. The sample size function is either
symmetric about the midpoint of the continuation region at the adaptation analysis or based on maintaining
conditional power (CP) at 90%, and is subject to the restriction of either a 50% or 100% maximal increase
relative to the final sample size of the reference group sequential design.
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(a) Symmetric NJ function, up to 50% Increase
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0.0 0.2 0.4 0.6 0.8 1.0
0.
90
0.
95
1.
00
1.
05
Power
Pr
op
.
 
of
 S
M 
Ex
pe
cte
d C
I H
alf
 Le
ng
th
SM
LR
BMP
(c) CP-based NJ function, up to 50% Increase
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Figure 3.11: Expected half length of different confidence intervals, as a proportion of the expected half
length of the confidence interval based on the sample mean ordering, for pre-specified two-stage adaptive
tests derived from a Pocock group sequential design. The sample size function is either symmetric about the
midpoint of the continuation region at the adaptation analysis or based on maintaining conditional power
(CP) at 90%, and is subject to the restriction of either a 50% or 100% maximal increase relative to the final
sample size of the reference group sequential design.
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3.3.2 Point Estimates
First, we would like to verify through simulation that the median-unbiased estimates under the different
orderings of the outcome space are in fact median-unbiased. Table 3.2 displays the observed probabilities
that the true treatment effect θ exceeds each MUE across a range of two-stage adaptive designs. Similar
results were observed when additional design parameters were varied. These findings demonstrate that the
estimates are median-unbiased within simulation error: with 10,000 replications and a 50% true probability
that θ will exceed an MUE, the standard error of the simulated probability is 0.005.
Table 3.2: Simulated Probabilities of θ Exceeding Median-Unbiased Estimates at Selected Power Points for
a Range of Two-stage Adaptive Tests
OF Reference GSD Pocock Reference GSD
Power SM LR BMP SM LR BMP
Symmetric NJ function, up to 100% Increase
0.0250 0.5073 0.5061 0.5087 0.5099 0.5097 0.5087
0.5000 0.5061 0.5059 0.5041 0.5055 0.5049 0.5053
0.9000 0.5012 0.5002 0.5014 0.4996 0.5005 0.4971
Symmetric NJ function, up to 100% Increase
0.0250 0.4956 0.4993 0.4960 0.4983 0.4986 0.4960
0.5000 0.5082 0.5076 0.5081 0.5100 0.5093 0.5095
0.9000 0.5019 0.5006 0.4970 0.5034 0.5028 0.5011
CP-based NJ function, up to 50% Increase
0.0250 0.5078 0.5091 0.5084 0.4949 0.4946 0.4941
0.5000 0.5044 0.5046 0.5050 0.4980 0.4980 0.4972
0.9000 0.5092 0.5097 0.5062 0.4995 0.4978 0.4967
CP-based NJ function, up to 50% Increase
0.0250 0.4975 0.4997 0.4958 0.5032 0.5035 0.5025
0.5000 0.5079 0.5075 0.5064 0.5027 0.5027 0.5045
0.9000 0.5001 0.4981 0.5050 0.5105 0.5099 0.5094
As discussed in section 2.5, it is desirable for point estimates to be as accurate and precise as possi-
ble. Bias, variance, and mean squared error are typically used to evaluate competing methods. The relative
behavior of point estimates may depend on the adaptive sampling plan and the presumed treatment effect.
Absolute bias for the different estimates has been observed to be very small at intermediate treatment ef-
fects, but larger, typically approaching 5% of the alternative ∆, at extreme treatment effects. We show
representative actual levels of absolute bias for the bias adjusted mean, and MUEs based on the sample
mean, likelihood ratio, and conditional error orderings, in Figure 3.12. Subsequent figures display abso-
lute bias as a difference from that of the bias adjusted mean to facilitate comparisons between competing
methods. Figures 3.13 and 3.14 present relative absolute bias for two-stage adaptive designs derived from
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O’Brien and Fleming and Pocock group sequential designs, respectively, with varying functions for and re-
strictions on the maximal increase in the final sample size. The bias adjusted mean demonstrates lower bias
than all competing estimates at small and large treatment effects. The BAM’s absolute superiority margin
approaches 2 - 3% of ∆ for certain designs and treatment effects.
Figures 3.15 and 3.16 present analogous results with respect to mean squared error, computed as a
proportion of the MSE of the bias adjusted mean. These results demonstrate the the BAM tends to have
mean squared error ranging from approximately 1 to 20% lower than competing estimates, depending on
the sampling plan, treatment effect, and MUE being compared. The margin of superiority increases with
the potential sample size inflation and tends to be slightly larger for CP-based than symmetric sample size
modification rules. The superior behavior of the BAM with respect to MSE tends to be due to lower bias
at extreme treatment effects and decreased variance at intermediate treatment effects. Median-unbiased
estimates based on the likelihood ratio and sample mean orderings have up to approximately 15% lower
MSE than the MUE under the conditional error ordering. The likelihood ratio ordering-based MUE is
slightly superior (∼ 1−3%) to the sample mean ordering-based MUE in some settings, but similar in others.
The observed differences in behavior between competing point estimates tend to be greater for adaptive
sampling plans derived from O’Brien and Fleming than Pocock group sequential designs.
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(a) Symmetric NJ function, up to 50% Increase
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Figure 3.12: Absolute bias of different point estimates, for pre-specified two-stage adaptive tests derived
from an O’Brien and Fleming group sequential design. The sample size function is either symmetric about
the midpoint of the continuation region at the adaptation analysis or based on maintaining conditional power
(CP) at 90%, and is subject to the restriction of a 50% maximal increase relative to the final sample size of
the reference group sequential design.
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Figure 3.13: Absolute bias of different point estimates, as a difference from the absolute bias of the bias
adjusted mean, for pre-specified two-stage adaptive tests derived from an O’Brien and Fleming group se-
quential design. The sample size function is either symmetric about the midpoint of the continuation region
at the adaptation analysis or based on maintaining conditional power (CP) at 90%, and is subject to the
restriction of either a 50% or 100% maximal increase relative to the final sample size of the reference group
sequential design.
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Figure 3.14: Absolute bias of different point estimates, as a difference from the absolute bias of the bias
adjusted mean, for pre-specified two-stage adaptive tests derived from a Pocock group sequential design.
The sample size function is either symmetric about the midpoint of the continuation region at the adaptation
analysis or based on maintaining conditional power (CP) at 90%, and is subject to the restriction of either a
50% or 100% maximal increase relative to the final sample size of the reference group sequential design.
http://biostats.bepress.com/uwbiostat/paper388
40
0.0 0.2 0.4 0.6 0.8 1.0
1.
00
1.
05
1.
10
1.
15
1.
20
1.
25
1.
30
1.
35
Power
Pr
op
or
tio
n 
of
 B
AM
 M
ea
n 
Sq
ua
re
d E
rro
r BAMSM MUE
LR MUE
BMP MUE
(a) Symmetric NJ function, up to 50% Increase
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Figure 3.15: Mean squared error of different point estimates, as a proportion of the mean squared error of the
bias adjusted mean, for pre-specified two-stage adaptive tests derived from an O’Brien and Fleming group
sequential design. The sample size function is either symmetric about the midpoint of the continuation
region at the adaptation analysis or based on maintaining conditional power (CP) at 90%, and is subject to
the restriction of either a 50% or 100% maximal increase relative to the final sample size of the reference
group sequential design.
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Figure 3.16: Mean squared error of different point estimates, as a proportion of the mean squared error of
the bias adjusted mean, for pre-specified two-stage adaptive tests derived from a Pocock group sequential
design. The sample size function is either symmetric about the midpoint of the continuation region at the
adaptation analysis or based on maintaining conditional power (CP) at 90%, and is subject to the restriction
of either a 50% or 100% maximal increase relative to the final sample size of the reference group sequential
design.
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3.3.3 P-values
As discussed in section 2.5, it may be of interest in some RCT design settings to consider the probabilities of
P-values falling below certain thresholds. For example, a P-value below 0.0252 = 0.000625, accompanied
by clear evidence of a clinically favorable benefit to risk profile, may be considered by the FDA to carry
the strength of statistical evidence of two independent confirmatory trials and thus qualify the study as
“pivotal.” Figures 3.17 and 3.18 present the probabilities of observing P-values below 0.001 and 0.000625,
for two-stage adaptive designs derived from O’Brien and Fleming and Pocock group sequential designs,
respectively, with varying functions for and restrictions on the maximal increase in the final sample size.
These results demonstrate that the likelihood ratio ordering produces low P-values with substantially higher
probabilities, up to 20% greater on the absolute scale, than the sample mean and conditional error orderings.
This superiority margin increases with the potential sample size inflation, and tends to be larger for CP-
based than symmetric sample size modification rules, and for adaptive sampling plans derived from O’Brien
and Fleming as compared to Pocock reference designs. These results also indicate that the sample mean
ordering is superior to the conditional error ordering with respect to this criterion in some settings, as it
yields up to approximately 10% higher probabilities, on the absolute scale, of observing P-values below
important thresholds.
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Figure 3.17: Probabilities of obtaining P-values below important thresholds, for pre-specified two-stage
adaptive tests derived from an O’Brien and Fleming group sequential design. The sample size function
is either symmetric about the midpoint of the continuation region at the adaptation analysis or based on
maintaining conditional power at 90%, and is subject to the restriction of either a 50% or 100% maximal
increase relative to the final sample size of the reference group sequential design.
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Figure 3.18: Probabilities of obtaining P-values below important thresholds, for pre-specified two-stage
adaptive tests derived from a Pocock group sequential design. The sample size function is either symmetric
about the midpoint of the continuation region at the adaptation analysis or based on maintaining conditional
power at 90%, and is subject to the restriction of either a 50% or 100% maximal increase relative to the final
sample size of the reference group sequential design.
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3.3.4 Varying Additional Design Parameters
Detailed results were presented in sections 3.3.1 through 3.3.3 on the relative behavior of inferential proce-
dures for simple two-stage adaptive sampling plans derived from symmetric group sequential designs with
two equally spaced interim analyses and power 90% at θ = ∆. We have already varied the conservatism of
the early stopping boundaries (O’Brien and Fleming versus Pocock), the type of sample size modification
rule (symmetric versus conditional power-based), and the degree of potential sample size inflation (50%
to 100% increase in the originally planned final sample size). Next, we explore whether additional design
parameters influence the trends observed in the previous sections. As discussed in section 3.1, we would
like to investigate the impact on inference of modifying the timing of the adaptation, the symmetry of the
reference group sequential design, and the power of the design at the alternative θ = ∆. While allowing
these parameters to vary, we present results for two-stage adaptive sampling plans derived from O’Brien
and Fleming group sequential designs, with either symmetric or conditional power-based sample size mod-
ification rules subject to the restriction of no greater than a 50% maximal increase in the final sample size.
The trends illustrated in these figures are representative of those observed for Pocock-based designs, as well
as for adaptive sampling plans allowing greater sample size inflation - these additional results can be found
in Appendix B (Figures B.1 through B.12).
We vary the timing of the adaptation by considering reference two-stage group sequential designs in
which the interim adaptation analysis is conducted at 25% (early) or 75% (late) of the originally planned
final sample size. Figures 3.19 and 3.20 compare properties of estimates, intervals, and P-values for adaptive
sampling plans with early and late adaptations, respectively. In the presence of either an early or late
adaptation, the trends observed previously generally persist, but quantitative differences between competing
methods decrease. Also of note, when the adaptation occurs early in the trial, the relative behavior of
inference based on the conditional error ordering improves. The MUE remains substantially inferior to
other point estimates with respect to MSE, but CIs tend to be shorter than those based on the sample mean
ordering, and nearly match the expected length of those under the likelihood ratio ordering. In addition,
although it is difficult to see this in Figure 3.19, the early-adaptation sampling plan is the only design for
which we have seen the conditional error order to approach the LR ordering with respect to the probability
of observing low P-values.
We additionally vary the symmetry of the superiority and non-superiority stopping boundaries at the
first analysis of the reference group sequential design. In order to do so, we derive adaptive sampling
plans from reference group sequential designs with early stopping only for superiority. Early stopping
only for superiority in a sense represents the greatest potential degree of asymmetry. Figure 3.21 presents
the behavior of inference after an adaptive sampling plan derived from an O’Brien and Fleming two-stage
group sequential design with early stopping only for superiority. Qualitative trends generally persist, but
the quantitative differences between the different orderings with respect to the MSE of point estimates and
expected length of CIs tends to be smaller in the presence of asymmetric early stopping boundaries. In
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particular, the sample mean and conditional error orderings now produce point and interval estimates with
very similar properties.
Finally, we consider adaptive designs with different levels of power at the alternative hypothesis of
interest θ = ∆. We have varied the power from 80% to 97.5%, and found very similar results to those
described in 3.3.1 through 3.3.3. This is not surprising - we chose to graphically present the properties of
different estimates against the power attained at the presumed treatment effect with the specific motivation of
being able to generalize the relative behavior to designs with other power curves and alternatives of interest.
All designs have 80%, 90%, and 97.5% at some values of the treatment effect. Figure 3.22 presents the
behavior of inference for two adaptive sampling plans derived from a group sequential design with 80%
power at θ = ∆. Also of note, Figures 3.19 through 3.22 again demonstrate that quantitative differences in
performance between competing methods tend to be greater for conditional power-based, as compared to
symmetric sample size modification rules.
In summary, when varying the timing of the adaptation, the asymmetry of early stopping boundaries,
and the power of the adaptive design, the qualitative differences between inferential methods described in
sections 3.3.2 through 3.3.3 generally persist. There are some notable changes - the relative behavior of
the BMP ordering tends to improve in the presence of early or late adaptations, and in the case of early
stopping only for superiority. That being said, the general findings still hold, as the likelihood ratio ordering
tends to produce estimates with lower MSE, shorter confidence intervals, and higher probabilities of low
P-values than competing orderings for nearly all plausible treatment effects. In addition, the bias adjusted
mean continues to demonstrate superior behavior to competing median-unbiased estimates.
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Figure 3.19: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with an early adaptation at 25% of the originally planned maximal sample size. The sam-
ple size function is either symmetric or based on conditional power (CP), and is subject to the restriction of
no greater than a 50% increase in the final sample size.
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Figure 3.20: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with a late adaptation at 75% of the originally planned maximal sample size. The sample
size function is either symmetric or based on conditional power (CP), and is subject to the restriction of no
greater than a 50% increase in the final sample size.
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Figure 3.21: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with early stopping only for superiority. The sample size function is either symmetric or
based on conditional power (CP), and is subject to the restriction of no greater than a 50% increase in the
final sample size.
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Figure 3.22: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with 80% at θ= ∆. The sample size function is either symmetric or based on conditional
power (CP), and is subject to the restriction of no greater than a 50% increase in the final sample size.
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3.4 Comparisons for Adaptive Designs with More than Two Stages
In section 3.3, we presented and discussed results for adaptive sampling plans with only two stages. Al-
though this is the most frequent type of adaptive design proposed in the literature, it remains of interest to
examine whether relative behavior depends on the number of interim analyses. To explore this, we con-
sider reference group sequential designs with four equally spaced interim analyses. Figure 3.23 presents the
relative behavior of inference when the adaptation occurs at the third (penultimate) analysis of a reference
O’Brien and Fleming design. The sample size function is either symmetric or based on maintaining condi-
tional power at 90%, and is subject to the restriction of a 50% maximal increase in the originally planned
final sample size. The findings are very similar to those of the analogous two-stage adaptive design, pre-
sented in Figures 3.8, 3.13, 3.15, and 3.17. The bias adjusted mean demonstrates superior behavior with
respect to MSE, and the likelihood ratio ordering produces confidence intervals and P-values with the best
properties. Similar results (Figures B.13 through B.15 in Appendix B) were observed for adaptive sampling
plans derived from a reference Pocock design, and for designs permitting greater sample size inflation.
Next, we consider adaptive sampling plans derived from four-analysis group sequential designs, in which
the adaptation occurs at the first analysis. The number of analyses after the adaptation is dynamic - the
original spacing of the interim analyses is maintained so that, for example, a 50% increase in the final
sample size yields a sample path with up to six analyses. Therefore, a design with a sample size modification
function allowing between a 25% decrease and 100% increase in the maximal sample size contains potential
sample paths with a maximum of between three and eight analyses.
Figure 3.24 presents the behavior of different inferential methods when the adaptation occurs at the first
analysis of a reference four-analysis O’Brien and Fleming design, and the sample size function is based on
maintaining conditional power subject to either a maximal 50% or 100% increase. The stopping boundaries
after the adaptation analysis along each potential path are determined by designing a “secondary” post-
adaptation Pocock design with type I error equal to the conditional error under the reference GSD. This type
of design is similar to many that have been proposed in the literature (Mu¨ller & Scha¨fer, 2001; Brannath et
al., 2009; Gao et al., 2012). Qualitative differences between the inferential procedures persist, although the
margins of superiority for the bias adjusted mean and likelihood ratio-based P-values decrease slightly.
As an aside, we note that we do not recommend the arbitrary choice of a complex adaptive design
such as the one for which results are presented and discussed here. We simply use this design as a tool to
study the relative behavior of inference for multi-stage adaptive sampling plans similar to ones frequently
proposed by other statisticians. The implications on the monotonicity of stopping boundaries or on important
operating characteristics of, for example, choosing Pocock-type stopping boundaries for secondary post-
adaptation group sequential paths is not at all intuitive or well-understood. When applying the conditional
error approach, even though all possible secondary designs impose Pocock stopping rules, differences in
conditional type I error rates across the potential sample paths result in vastly different boundaries. As
a simple example, consider a design with an adaptation at the first analysis of a reference four-analysis
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Pocock group sequential design. The sample size function is based on maintaining conditional power at
90% subject to a 100% maximal increase. The stopping boundaries after the adaptation analysis along each
potential path are determined by designing secondary post-adaptation Pocock designs with type I error equal
to the conditional error under the reference GSD.
At first glance, this may seem like a reasonable sampling plan. However, more careful examination
reveals likely unacceptable non-monotonicity and incompatibility between boundaries through different
sample paths. For example, three of the possible sample paths result in violations of monotonicity of the
non-superiority boundaries on the sample mean scale - the boundaries at the second analysis are actually
less than those at the first analysis, despite the increase in statistical information. In addition, estimates
of treatment effect that would result in stopping early for superiority through one path may result in stop-
ping early with the opposite decision through another path. For example, one interim analysis superiority
threshold on the sample mean scale is 0.51∆, while a threshold through a different path for an early decision
of non-superiority is 0.69∆. This type of behavior argues that investigators should exercise extreme care
when considering possible adaptive sampling plans, because the potentially adverse and substantial impact
of complex adaptation rules on boundaries and operating characteristics is not at all well-understood.
In summary, our findings suggest that the qualitative differences between competing inferential proce-
dures observed for simple two-stage adaptive sampling plans persist when the number of interim analyses
is increased. Similar trends are observed whether the adaptation occurs at an early or late interim analysis,
and even if the number of potential group sequential analyses after the adaptation is dynamic and subject
to substantial variability. We do note that our investigations of multi-stage adaptive sampling plans are not
nearly as comprehensive as in the two-stage setting, and that our findings remain focused on designs with a
single adaptation analysis.
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Figure 3.23: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with a maximum of four analyses. The adaptation occurs at the third interim analysis. The
sample size function is either symmetric or based on conditional power (CP), and is subject to the restriction
of no greater than a 50% increase in the final sample size.
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Figure 3.24: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with a maximum of four analyses. The adaptation occurs at the first interim analysis, and
adaptively chosen sample paths consist of between two and eight interim analyses. The sample size function
is based on maintaining conditional power at 90%, and is subject to the restriction of no greater than either
a 50% or 100% increase in the final sample size.
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3.5 Statistical Reliability of Estimated Differences in Performance of Infer-
ence
It is of interest to investigate whether the differences in performance estimated by simulation experiments
provide reliable statistical evidence of true differences between the inferential methods. All of the figures
presented in the previous sections are based on the results of 10,000 simulations at each of 50 potential
treatment effects spanning a wide range of the parameter space. We have computed the estimated variance
and covariance of many of the estimated performance quantities in order to investigate the statistical credi-
bility of estimated differences. The short answer is that even the smallest separation that can be observed in
the figures provides strong statistical evidence against no difference. For example, consider representative
comparisons of the bias of point estimates and expected length of confidence intervals displayed in Figure
3.25. The comparisons identified by the red circles represent extremely small vertical separations between
the performance of estimates under the likelihood ratio and conditional error orderings. The identified esti-
mated difference in bias at the 2.5% power point, i.e., under the null hypothesis, for this particular adaptive
design, is 0.0025∆. The estimated difference in expected CI length at the 50% power point, identified by
the red circle in Figure 3.25(b), is 0.0041∆. It is important to understand the degree of precision we have
in these estimates and whether they are statistically significantly different from zero. We can estimate the
variance of the estimated differences in bias and expected CI length (l) from n simulations as follows:
v̂ar
[
̂E(θ˜BMP−θ)−E(θ˜LR−θ)
]
=
1
n
v̂ar[ θ˜BMP ]+
1
n
v̂ar[ θ˜LR ]− 2n ĉov[ θ˜BMP, θ˜LR ],
v̂ar
[
̂E(lBMP)−E(lLR)
]
=
1
n
v̂ar[ lBMP ]+
1
n
v̂ar[ lLR ]− 2n ĉov[ lBMP, lLR ]. (3.1)
Applying these formulas, we compute 99% confidence intervals for the estimated differences in bias
and length: (0.00075∆,0.0042∆) and (0.0039∆,0.0043∆), respectively. Therefore, even these small vertical
separations, barely visible to the eye in the figures, are inconsistent with a lack of true difference in perfor-
mance between the two orderings. We note that these are 99% confidence intervals for comparisons at a
single presumed treatment effect, not confidence intervals with joint coverage for a comparison of the entire
curves. That being said, in most comparisons presented in previous sections, the performance of one method
is superior to that of alternative methods across large contiguous sections or the entire range of treatment
effects we considered. Because we have carried out independent simulations under a large number (50) of
treatment effects, we would expect periodic crossing of the curves in the absence of statistically reliable
differences between competing methods. This in fact does occur for the few settings (typically with respect
to bias) for which there are no clear differences between competing estimates. In addition, the majority of
the differences in performance we have observed between methods are much larger than the negligible yet
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Figure 3.25: Absolute bias of point estimates and expected length of confidence intervals for two adaptive
sampling plans. The red circles identify very small estimated differences in performance between the like-
lihood ratio and BMP orderings that are used as examples in the text to discuss the statistical reliability of
comparisons.
still statistically significant differences used as examples here. Therefore, it is clear that the findings in this
chapter regarding the relative behavior of different inferential procedures are based on statistically reliable
results. It is important to note that the differences displayed in Figure 3.25 are not scientifically meaningful.
We base important conclusions in the following section on differences in performance that are substantially
larger in magnitude and thus are both scientifically and statistically significant.
3.6 Conclusions and the Cost of Planning not to Plan
In this chapter, we used a comprehensive adaptive design comparison framework to evaluate and compare
the behavior of several inferential methods with respect to a range of important optimality criteria. Through
extensive simulation experiments, we investigated the impact of varying numerous parameters of an adaptive
sampling plan on the relative performance of estimates and P-values across a wide range of plausible treat-
ment effects. Some inferential procedures were observed to behave quite poorly relative to the alternatives.
As expected, the maximum likelihood (sample mean) point estimate and naive fixed sample confidence in-
terval demonstrated many undesirable properties. The MLE has substantially higher bias than many other
estimates at all but intermediate treatment effects, and considerably higher mean squared error (up to∼ 40%
higher) across nearly all designs and treatments effects we considered. Naive 95% confidence intervals do
not have exact coverage, with observed coverage probabilities typically 92-94%, and occasionally near 90%.
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This performance is not terrible, but it remains a better choice to use methods adjusting for the sequential
sampling plan. In addition, stage-wise orderings of the outcome space based on the analysis time or statisti-
cal information at stopping produce estimates and P-values with generally inferior behavior to comparators
under alternative orderings.
The bias adjusted mean demonstrates the best behavior among candidate point estimates, with lower bias
at extreme treatment effects and lower mean squared error (up to∼ 20% lower) across nearly all designs and
treatment effects considered. The likelihood ratio ordering tends to produce median-unbiased estimates with
lower MSE, confidence intervals with shorter expected length, and higher probabilities of low P-values than
the sample mean and conditional error orderings. In particular, LR ordering-based P-values demonstrate
substantially (up to ∼ 20% absolute) higher probabilities of reaching “pivotal” levels than those based on
alternative orderings. The superiority margin for inference based on the LR ordering tends to be larger for
greater sample size increases, and for conditional power-based than symmetric modification rules. Sample
mean ordering-based inference behaves similar to or slightly better than inference under the conditional
error ordering in most settings.
Our comparisons clearly do not encompass the full space of potential adaptive designs, so it remains
critical to rigorously investigate candidate sampling plans and inferential procedures in any unique RCT
setting where an adaptive design is under consideration. Nevertheless, we have observed clear patterns that
motivate some general conclusions and recommendations in the presence of a pre-specified adaptive sam-
pling plan from the class of designs described in section 1.3. The bias adjusted mean is the recommended
point estimate due to its superior accuracy and precision than the MLE and competing median-unbiased es-
timates. In addition, computation of confidence intervals and P-values based on the likelihood ratio ordering
is supported by superior behavior with respect to important optimality criteria across the range of designs
and treatment effects studied. However, adaptive hypothesis testing based on the likelihood ratio and BMP
orderings typically results in a wide range of potential thresholds for statistical significance (see, e.g., Figure
3.3). This range of thresholds may include values that fall below the minimal clinically important difference
(MCID). As a result, we have found that sample mean-based inference tends to demonstrate superior behav-
ior to alternative orderings when considering not statistical power, but instead the probability of obtaining
an estimate at the end of the trial that is both statistically and clinically significant. This consideration alone
may warrant the choice of sample mean-based rather than likelihood ratio-based inference in the presence
of a pre-specified adaptive design.
Our results also directly quantify what we describe as the “cost of planning not to plan.” In many
settings, if sample size modifications are of interest, the adaptive sampling plan and method of inference
could easily be and may need to be pre-specified. If the goal of an adaptation is truly to maintain conditional
power at some desired level, there is little reason why the sampling plan could not be established at the
design stage. In addition, the use of an unplanned adaptation to increase the sample size (and budget) of
a clinical trial may not be feasible for government or foundation-funded studies. The implementation of
unplanned adaptations is also logistically difficult and discouraged by the FDA.
http://biostats.bepress.com/uwbiostat/paper388
58
If adaptations are not pre-specified, the conditional error (BMP) ordering is the only method we have
considered that allows the computation of median-unbiased estimates, confidence intervals with approxi-
mately exact coverage, and P-values uniformly distributed on [0,1]. On the other hand, if adaptations are in
fact pre-specified, any of the candidate orderings of the outcome space could be used at stopping to com-
pute estimates and P-values. Therefore, by evaluating the relative behavior of inference based on the BMP
and alternative orderings under pre-specified adaptive sampling plans, we can quantify the cost of failing
to pre-specify the adaptation rule and thus needing to implement BMP ordering-based inference. Our re-
sults suggest that there is always a non-negligible cost of planning not to plan, and at times the cost can
be substantial. Conditional error ordering-based confidence intervals actually demonstrate reasonably sim-
ilar performance to those based on the likelihood ratio ordering, with exact coverage and expected lengths
typically only about 5% greater. However, the BMP MUE has substantially higher mean squared error (up
to ∼ 25% higher) than the competing bias adjusted mean, and the BMP P-value attains substantially lower
probabilities (up to ∼ 20% lower) than the LR P-value of falling below important thresholds. In addition,
these losses are greatest when sample size modification rules are based on conditional power and allow
large inflation, i.e., for the kinds of sampling plans most typically proposed in the literature. If an unplanned
sample size modification is conducted during a clinical trial, the BMP conditional error approach seems
like a reasonable (and necessary) choice. However, if an adaptation could instead be pre-specified at the
design stage, inference involving the bias adjusted mean and either the sample mean or likelihood ratio
ordering-based CIs and P-values will tend to result in superior reliability and precision.
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Appendix A
Proof of Stochastic Ordering in θ under
Sample Mean Ordering
The proof that the sample mean ordering of the outcome space is stochastically ordered in θ in the pre-
specified adaptive setting is easily generalized from Emerson’s proof (1988) in the group sequential setting.
We will make use of the following lemma:
Lemma A. Consider a pre-specified adaptive hypothesis test as described in chapter 1. Then
ES[S; θ ] = θEN [N; θ ].
Proof. Define pM,S,K( j, s, k; θ) as in equation (1.3). Without loss of generality, let σ2 = 0.5. We have that
EN [N; θ ] =
h
∑
j=1
n0j
∞∫
−∞
p( j, s, 0;θ) ds+
r
∑
k=1
Jk
∑
j=h+1
nkj
∞∫
−∞
p( j, s, k;θ) ds
=
h
∑
j=1
n0j P[M = j,K = 0; θ ]+
r
∑
k=1
Jk
∑
j=h+1
nkj P[M = j,K = k; θ ]
=
h
∑
j=1
n0∗j P[M ≥ j,K = 0; θ ]+
r
∑
k=1
Jk
∑
j=h+1
nk∗j P[M ≥ j,K = k; θ ].
ES[S; θ ] =
h
∑
j=1
∞∫
−∞
s p( j, s, 0;θ) ds+
r
∑
k=1
Jk
∑
j=h+1
∞∫
−∞
s p( j, s, k;θ) ds
=
h
∑
j=1
∫
S0(0)j ∪S
0(1)
j
s f ( j, s, 0;θ) ds+
r
∑
k=1
Jk
∑
j=h+1
∫
S k(0)j ∪S
k(1)
j
s f ( j, s, k;θ) ds
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=
∫
S0(0)h ∪S
0(1)
h
∫
C0h−1
s√
2n0∗h
φ
 s−u−n0∗h θ√
2n0∗h
 f (h−1, u, 0; θ) duds+ h−1∑
j=1
∫
S0(0)j ∪S
0(1)
j
s f ( j, s, 0;θ) ds
+
r
∑
k=1
∞∫
−∞
∫
CkJk−1
s√
2nk∗Jk
φ
 s−u−nk∗Jk θ√
2nk∗Jk
 f (Jk−1, u, k; θ) duds+ r∑
k=1
Jk−1
∑
j=h+1
∫
S k(0)j ∪S
k(1)
j
s f ( j, s, k;θ) ds
=
∫
S0(0)h ∪S
0(1)
h
∫
C0h−1
s√
2n0∗h
φ
 s−u−n0∗h θ√
2n0∗h
 f (h−1, u, 0; θ) duds+ h−1∑
j=1
∫
S0(0)j ∪S
0(1)
j
s f ( j, s, 0;θ) ds
+
r
∑
k=1
∫
CkJk−1
(u+nk∗Jk θ) f (Jk−1, u, k; θ) du+
r
∑
k=1
Jk−1
∑
j=h+1
∫
S k(0)j ∪S
k(1)
j
s f ( j, s, k;θ) ds
=
∫
S0(0)h ∪S
0(1)
h
∫
C0h−1
s√
2n0∗h−1
φ
 s−u−n0∗j θ√
2n0∗j
 f (h−1, u, 0; θ) duds+ h−1∑
j=1
∫
S0(0)j ∪S
0(1)
j
s f ( j, s, 0;θ) ds
+
r
∑
k=1
nk∗j θP[M ≥ Jk,K = k; θ ]+
r
∑
k=1
∞∫
−∞
∫
CkJk−2
s√
2nk∗Jk−1
φ
 s−u−nk∗Jk−1 θ√
2nk∗Jk−1
 f (Jk−2, u, k; θ) duds
+
r
∑
k=1
Jk−2
∑
j=h+1
∫
S k(0)j ∪S
k(1)
j
s f ( j, s, k;θ) ds
...
=
∫
S0(0)h ∪S
0(1)
h
∫
C0h−1
s√
2n0∗h−1
φ
 s−u−n0∗j θ√
2n0∗j
 f (h−1, u, 0; θ) duds+ h−1∑
j=1
∫
S0(0)j ∪S
0(1)
j
s f ( j, s, 0;θ) ds
+
r
∑
k=1
Jk
∑
j=h+2
nk∗j θP[M ≥ j,K = k; θ ]+
r
∑
k=1
∞∫
−∞
∫
Ckh
s√
2nk∗h+1
φ
 s−u−nk∗h+1 θ√
2nk∗h+1
 f (h, u, k; θ) duds
=
∞∫
−∞
∫
C0h−1
s√
2n0∗h−1
φ
 s−u−n0∗j θ√
2n0∗j
 f (h−1, u, 0; θ) duds+ h−1∑
j=1
∫
S0(0)j ∪S
0(1)
j
s f ( j, s, 0;θ) ds
+θ(
r
∑
k=1
Jk
∑
j=h+1
nk∗j P[M ≥ j,K = k; θ ] )
...
= θ(
h
∑
j=1
n0∗j P[M ≥ j,K = 0; θ ]+
r
∑
k=1
Jk
∑
j=h+1
nk∗j P[M ≥ j,K = k; θ ] )
= θEN [N; θ ].
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We can use this result to help prove the following theorem.
Theorem A. Consider a pre-specified adaptive hypothesis test as described in chapter 1, with θ the unknown
parameter. Define T ≡ θˆ as the difference in sample means. Then, for any t, P[T > t; θ ] is a monotonically
increasing function of θ, i.e., T is stochastically ordered in θ.
Proof. Define pM,S,K( j, s, k; θ) as in equation (1.3). Without loss of generality, let σ2 = 0.5. T = S/N, so
we have that
P[T > t; θ ] =
h
∑
j=1
∞∫
n0j t
p( j, s, 0; θ) ds+
r
∑
k=1
Jk
∑
j=h+1
∞∫
nkj t
p( j, s, k; θ) ds.
Continuity holds because the functions f ( j, s, k; θ) are continuous, and p(Jk, s, k; θ) = f (Jk, s, k; θ) for
k = 1, . . . ,r. Using relation (1.4), we can see that
∂
∂u
p( j, s, k; θ) = (s−nkj θ) p( j, s, k; θ).
Therefore,
∂
∂u
P[T > t; θ ] =
h
∑
j=1
∞∫
n0j t
(s−n0j θ) p( j, s, 0; θ) ds+
r
∑
k=1
Jk
∑
j=h+1
∞∫
nkj t
(s−nkj θ) p( j, s, k; θ) ds
=
h
∑
j=1
 ∞∫
−∞
(s−n0j θ) p( j, s, 0; θ) ds−
n0j t∫
−∞
(s−n0j θ) p( j, s, 0; θ) ds

+
r
∑
k=1
Jk
∑
j=h+1
 ∞∫
−∞
(s−nkj θ) p( j, s, k; θ) ds−
nkj t∫
−∞
(s−nkj θ) p( j, s, k; θ) ds

= ES[S; θ ]−θEN [N; θ ]+
h
∑
j=1
n0j t∫
−∞
(n0j θ− s) p( j, s, 0; θ) ds+
r
∑
k=1
Jk
∑
j=h+1
nkj t∫
−∞
(nkj θ− s) p( j, s, k; θ) ds
=
h
∑
j=1
n0j t∫
−∞
(n0j θ− s) p( j, s, 0; θ) ds+
r
∑
k=1
Jk
∑
j=h+1
nkj t∫
−∞
(nkj θ− s) p( j, s, k; θ) ds,
by applying Lemma A. If t ≥ θ, then
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∞∫
nkj t
(s−nkj θ) p( j, s, k; θ) ds≥ nkj (t−θ)P[S > nkj t,M = j,K = k; θ ]≥ 0
and if t ≤ θ, then
nkj t∫
−∞
(nkj θ− s) p( j, s, k; θ) ds≥ nkj (θ− t)P[S < nkj t,M = j,K = k; θ ]≥ 0
for k = 0, j = 1, . . . ,h and k = 1, . . . ,r, j = h+1, . . . ,Jk−1. In addition, for k = 1, . . . ,r, j = Jk,
nkJk t∫
−∞
(nkJk θ− s) p(Jk, s, k; θ) ds > 0
because p(Jk, s, k; θ) > 0 for all s. Therefore, the derivative is positive and T is stochastically ordered
in θ.
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Appendix B
Additional Results
The following figures supplement the results that were presented in chapter 3.
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Figure B.1: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with an early adaptation at 25% of the originally planned maximal sample size. The sample size function
is either symmetric or based on conditional power (CP), and is subject to the restriction of no greater than a
50% increase in the final sample size.
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Figure B.2: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group se-
quential design with an early adaptation at 25% of the originally planned maximal sample size. The sample
size function is either symmetric or based on conditional power (CP), and is subject to the restriction of no
greater than a 100% increase in the final sample size.
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Figure B.3: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with an early adaptation at 25% of the originally planned maximal sample size. The sample size function
is either symmetric or based on conditional power (CP), and is subject to the restriction of no greater than a
100% increase in the final sample size.
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Figure B.4: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with a late adaptation at 75% of the originally planned maximal sample size. The sample size function is
either symmetric or based on conditional power (CP), and is subject to the restriction of no greater than a
50% increase in the final sample size.
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Figure B.5: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with a late adaptation at 75% of the originally planned maximal sample size. The sample
size function is either symmetric or based on conditional power (CP), and is subject to the restriction of no
greater than a 100% increase in the final sample size.
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Figure B.6: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with a late adaptation at 75% of the originally planned maximal sample size. The sample size function is
either symmetric or based on conditional power (CP), and is subject to the restriction of no greater than a
100% increase in the final sample size.
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Figure B.7: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with early stopping only for superiority. The sample size function is either symmetric or based on conditional
power (CP), and is subject to the restriction of no greater than a 50% increase in the final sample size.
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Figure B.8: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with early stopping only for superiority. The sample size function is either symmetric or
based on conditional power (CP), and is subject to the restriction of no greater than a 100% increase in the
final sample size.
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Figure B.9: Mean squared error of point estimates, expected length of confidence intervals, and probabilities
of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with early stopping only for superiority. The sample size function is either symmetric or based on conditional
power (CP), and is subject to the restriction of no greater than a 100% increase in the final sample size.
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Figure B.10: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with 80% Power at θ= ∆. The sample size function is either symmetric or based on conditional power (CP),
and is subject to the restriction of no greater than a 50% increase in the final sample size.
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Figure B.11: Mean squared error of point estimates, expected length of confidence intervals, and probabil-
ities of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with 80% Power at θ= ∆. The sample size function is either symmetric or based on con-
ditional power (CP), and is subject to the restriction of no greater than a 100% increase in the final sample
size.
http://biostats.bepress.com/uwbiostat/paper388
78
0.0 0.2 0.4 0.6 0.8 1.0
1.0
0
1.0
5
1.1
0
1.1
5
1.2
0
1.2
5
1.3
0
1.3
5
Power
Pr
op
or
tio
n o
f B
AM
 M
ea
n S
qu
are
d E
rro
r BAMSM MUE
LR MUE
BMP MUE
(a) Mean Squared Error, Symmetric NJ function
0.0 0.2 0.4 0.6 0.8 1.0
1.0
0
1.0
5
1.1
0
1.1
5
1.2
0
1.2
5
1.3
0
1.3
5
Power
Pr
op
or
tio
n o
f B
AM
 M
ea
n S
qu
are
d E
rro
r BAMSM MUE
LR MUE
BMP MUE
(b) Mean Squared Error, CP-based NJ function
0.0 0.2 0.4 0.6 0.8 1.0
0.9
0
0.9
5
1.0
0
1.0
5
Power
Pr
op
or
tio
n o
f S
M 
Ex
pe
cte
d C
I L
en
gth
SM
LR
BMP
(c) Expected Length, Symmetric NJ function
0.0 0.2 0.4 0.6 0.8 1.0
0.9
0
0.9
5
1.0
0
1.0
5
Power
Pr
op
or
tio
n o
f S
M 
Ex
pe
cte
d C
I L
en
gth
SM
LR
BMP
(d) Expected Length, CP-basd NJ function
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Treatment Effect θ
Pr
ob
ab
ilit
y o
f L
ow
 P
−v
alu
e
0 0.25∆ 0.5∆ 0.75∆ ∆ 1.25∆
SM
LR
BMP
< 0.001
< 0.000625
(e) Low P-values, Symmetric NJ function
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Treatment Effect θ
Pr
ob
ab
ilit
y o
f L
ow
 P
−v
alu
e
0 0.25∆ 0.5∆ 0.75∆ ∆
SM
LR
BMP
< 0.001
< 0.000625
(f) Low P-values, CP-based NJ function
Figure B.12: Mean squared error of point estimates, expected length of confidence intervals, and probabili-
ties of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential design
with 80% Power at θ= ∆. The sample size function is either symmetric or based on conditional power (CP),
and is subject to the restriction of no greater than a 100% increase in the final sample size.
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Figure B.13: Mean squared error of point estimates, expected length of confidence intervals, and proba-
bilities of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential
design with a maximum of four analyses. The adaptation occurs at the third interim analysis. The sample
size function is either symmetric or based on conditional power (CP), and is subject to the restriction of no
greater than a 50% increase in the final sample size.
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Figure B.14: Mean squared error of point estimates, expected length of confidence intervals, and probabil-
ities of obtaining low P-values for pre-specified adaptive tests derived from an O’Brien and Fleming group
sequential design with a maximum of four analyses. The adaptation occurs at the third interim analysis. The
sample size function is either symmetric or based on conditional power (CP), and is subject to the restriction
of no greater than a 100% increase in the final sample size.
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Figure B.15: Mean squared error of point estimates, expected length of confidence intervals, and proba-
bilities of obtaining low P-values for pre-specified adaptive tests derived from a Pocock group sequential
design with a maximum of four analyses. The adaptation occurs at the third interim analysis. The sample
size function is either symmetric or based on conditional power (CP), and is subject to the restriction of no
greater than a 100% increase in the final sample size.
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